

Supporting Information © Wiley-VCH 2012

69451 Weinheim, Germany

Synthesis of Enantiomerically Enriched Imidazolidin-2-Ones through Asymmetric Palladium-Catalyzed Alkene Carboamination Reactions**

Brett A. Hopkins and John P. Wolfe*

anie_201205233_sm_miscellaneous_information.pdf

Table of Contents

General Considerations	S1
Synthesis of N-Allylurea Substrates	S2
Asymmetric Pd-Catalyzed Carboamination Reactions	S8
Deuterium Labeling Studies	S30
Discussion of Mechanism of Diastereomer Formation in the Reaction of (Z)-d-1f	S32
Determination of Stereochemistry	S34
References	S37

General: Reactions were carried out under nitrogen in flame-dried glassware. Tris(dibenzylideneacetone)dipalladium and (S)-Siphos-PE were purchased from Strem Chemical Co. and used without further purification. All other reagents including all aryl and alkenyl bromides were purchased from commercial sources and used as received unless otherwise noted. Xylenes were purified by distillation over CaH₂ prior to use in

reactions. Methylene chloride and toluene were purified using a GlassContour solvent system. All yields refer to isolated compounds that are estimated to be \geq 95% pure as judged by ¹H NMR analysis. The yields reported in the supporting information describe the result of a single experiment, whereas yields reported in Tables 1–2 and equations 2–4 are average yields of two or more experiments. Thus, the yields reported in the supporting information may differ from those shown in Table 2 and equations 2–4.

General procedure for the synthesis of *N*-allylurea substrates. A flame-dried round bottom flask equipped with a stirbar was cooled under a stream of nitrogen. The flask was charged with the appropriate isocyanate (1.0 equiv) and methylene chloride (0.60 M). The resulting solution was cooled to 0 °C and stirred for 5 min, then the allylic amine (1.1 equiv) was added dropwise. The solution was warmed to rt and stirred for five h. The mixture was then concentrated in vacuo and purified by flash chromatography on silica gel.

1-AllyI-3-{4-[benzyl(methyl)amino]phenyl}-1-methylurea (1a): A flame dried Schlenk flask equipped with a stirbar was cooled under a stream of nitrogen and charged with 1-allyI-3-(4-bromophenyl)-1-methylurea (1.00 g, 3.72 mmol), lithium bis(trimethylsilyl)amide (1.37 g, 4.46 mmol), Pd₂(dba)₃ (34.1 mg, 0.0372 mmol), and DavePhos (35.1 mg, 0.0893 mmol). The flask was purged with N₂ pressure for 30 s then THF (8.2 mL) and *N*-methyl benzylamine (0.58 mL, 4.46 mmol) were added. The

resulting mixture was heated to 65 °C with stirring for 15 h, then was cooled to rt. A solution of 1M HCl (8 mL) was added and the resulting mixture was stirred at rt for five min. A solution of saturated aqueous NaHCO₃ (8 mL) was slowly added and the mixture was transferred to a separatory funnel after bubbling ceased. The mixture was extracted with ethyl acetate (3 x 20 mL) then the combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel to afford 450 mg (40%) of the title compound as a light brown solid, mp 93–97 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.31–7.14 (m, 7H), 6.68 (d, J = 9.0 Hz, 2H), 6.18 (s, br, 1H), 5.83 (ddt, J = 5.5, 5.2, 12.0 Hz, 1H), 5.26–5.19 (m, 2H), 4.46 (s, 2H), 3.93 (d, J = 5.5 Hz, 2H), 2.96 (s, 3H), 2.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.2, 146.5, 138.9, 133.6, 128.8, 128.4, 126.8, 126.7, 122.5, 116.7, 113.0, 57.0, 51.4, 38.7, 34.4; IR (film) 1637 cm⁻¹. MS (CI) 310.1916 (310.1914 calcd for C₁₉H₂₃N₃O, M + H⁺).

1-AllyI-3-(4-methoxyphenyI)-1-methylurea (1b): The reaction of *N*-allylmethylamine (0.47 mL, 4.92 mmol) with 4-methoxyphenyl isocyanate (0.58 mL, 4.47 mmol) according to the general procedure afforded 841 mg (85%) of the title compound as a white solid, mp 52–55 °C. 1 H NMR (400 MHz, CDCl₃) δ 7.24 (d, J = 9.0 Hz, 2H), 6.81 (d, J = 9.0 Hz, 2H), 6.61 (s, br, 1H), 5.90–5.78 (m, 1H), 5.25 (d, J = 5.5 Hz, 1H), 5.22 (s, 1H), 3.94 (d, J = 5.3 Hz, 2H), 3.76 (s, 3H), 2.97 (s, 3H); 13 C NMR (100 MHz, CDCl₃) δ 155.8, 155.7,

133.5, 132.2, 122.1, 116.8, 114.0, 55.5, 51.5, 34.5; IR (film) 1638 cm $^{-1}$. MS (CI) 221.1280 (221.1285 calcd for $C_{12}H_{16}N_2O_2$, M + H $^+$).

1-AllyI-1-methyI-3-phenylurea (1c): The reaction of *N*-allylmethylamine (0.37 mL, 3.85 mmol) with phenyl isocyanate (0.42 mL, 3.50 mmol) according to the general procedure afforded 644 mg (88%) of the title compound as a white solid, mp 71–74 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 7.8 Hz, 2H), 6.98 (t, J = 7.4 Hz, 1H), 6.48 (s, br, 1H), 5.88–5.78 (m, 1H), 5.26–5.19 (m, 2H), 3.93 (d, J = 5.5 Hz, 2H), 2.96 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.6, 139.2, 133.4, 128.8, 122.9, 119.8, 116.9, 51.5, 34.5; IR (film) 1639 cm⁻¹. MS (CI) 191.1180 (191.1179 calcd for C₁₁H₁₄N₂O, M + H⁺).

1-AllyI-3-(4-bromophenyI)-1-methylurea (**1d**): The reaction of *N*-allylmethylamine (0.80 mL, 8.44 mmol) with 4-bromophenyl isocyanate (1.51 g, 7.67 mmol) according to the general procedure afforded 1.88 g (91%) of the title compound as a white solid, mp 123–126 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.32 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 8.9 Hz,

2H), 6.47 (s, br, 1H), 5.81 (ddt, J = 5.5, 5.6, 9.9 Hz, 1H), 5.27–5.19 (m, 2H), 3.92 (d, J = 5.3 Hz, 2H), 2.96 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.2, 138.3, 133.2, 131.7, 121.4, 117.0, 115.2, 51.5, 34.6; IR (film) 1634 cm⁻¹. MS (CI) 269.0282 (269.0284 calcd for C₁₁H₁₃BrN₂O, M + H⁺).

1-AllyI-3-(4-cyanophenyI)-1-methylurea (1e): The reaction of *N*-allylmethylamine (0.73 mL, 7.65 mmol) with 4-cyanophenyl isocyanate (1.00 g, 6.96 mmol) according to the general procedure afforded 1.17 g (78%) of the title compound as a white solid, mp 119–122 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.54 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 8.8 Hz, 2H), 6.69 (s, br, 1H), 5.86 (ddt, J = 5.1, 5.4, 11.9 Hz, 1H), 5.32–5.25 (m, 2H), 3.80 (d, J = 5.4 Hz, 2H), 3.03 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.6, 143.5, 133.1, 132.9, 119.2, 119.0, 117.4, 105.3, 51.6, 34.8; IR (film) 1664 cm⁻¹. MS (CI) 216.1135 (216.1131 calcd for $C_{12}H_{13}N_3O_3$, M + H⁺).

1-AllyI-1-methyI-3-(4-nitrophenyI)urea (1f): The reaction of *N*-allyImethylamine (0.77 mL, 8.09 mmol) with 4-nitrophenyl isocyanate (1.21 g, 7.35 mmol) according to the general procedure afforded 1.61 g (93%) of the title compound as a yellow solid, mp

78–81 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.10 (d, J = 9.2 Hz, 2H), 7.53 (d, J = 9.2 Hz, 2H), 7.00 (s, br, 1H), 5.84 (ddt, J = 5.3, 5.6, 11.4 Hz, 1H), 5.32–5.22 (m, 2H), 3.98 (d, J = 5.3 Hz, 2H), 3.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.7, 145.6, 142.2, 132.8, 125.0, 118.4, 117.4, 51.6, 34.8; IR (film) 1660 cm⁻¹. MS (CI) 236.1037 (236.1030 calcd for C₁₁H₁₃N₃O₃, M + H⁺).

1-Methyl-1-(2-methylallyl)-3-(4-nitrophenyl)urea (3): A flame dried flask equipped with a stirbar was cooled under a stream of nitrogen and charged with 3-bromo-2-methylpropene (4.60 mL, 45 mmol). The flask was cooled to 0 °C and stirred for five min, then methylamine (27.2 mL, 225 mmol, 33% solution in EtOH) was added and the resulting mixture was warmed to rt and stirred for 15 h. A solution of 1M NaOH (20 mL) was added and the resulting mixture was transferred to a separatory funnel. The mixture was extracted with ether (3 x 20 mL) then the combined organic layers were washed with 1M NaOH (1x12 mL), dried over anhydrous Na₂SO₄, filtered, and partially concentrated *in vacuo* (to remove excess methylamine) to afford *N*,2-dimethylprop-2-en-1-ylamine as a solution in ethanol. The solution was transferred to a flask equipped with a stirbar and cooled to -10 °C. Neat 4-nitrophenyl isocyanate (1.64 g, 10 mmol) was added and the resulting solution and the reaction was slowly warmed to rt over the course of five h. The reaction mixture was then concentrated in vacuo and the crude

product was purified by flash column chromatography to yield 350 mg (14 %) of the title compound as a yellow solid, mp 79–82 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.13 (d, J = 9.3 Hz, 2H), 7.52 (d, J = 9.1 Hz, 2H), 6.92 (s, br, 1H), 5.03 (s, 1H) 4.96 (s, 1H), 3.90 (s, 2H), 3.05 (s, 3H), 1.78 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.7, 145.5, 142.3, 141.0, 125.0, 118.3, 112.5, 55.2, 35.3, 19.7; IR (film) 1658 cm⁻¹. MS (CI) 250.1191 (250.1186 calcd for $C_{12}H_{15}N_3O_3$, M + H⁺).

1-Cinnamyl-1-methyl-3-(4-nitrophenyl)urea (5): A flame dried flask equipped with a stirbar was cooled under a stream of nitrogen and charged with cinnamyl bromide (4.33 g, 22 mmol). The flask was cooled to 0 °C and stirred for five min, then methylamine (27.2 mL, 225 mmol, 33% solution in EtOH) was added and the resulting mixture was warmed to rt and stirred for 15 h. A solution of 1M NaOH (20 mL) was added and the resulting mixture was transferred to a separatory funnel. The mixture was extracted with ether (3 x 20 mL) then the combined organic layers were washed with 1M NaOH (1x12 mL), dried over anhydrous Na₂SO₄, filtered, and partially concentrated *in vacuo* (to remove excess methylamine) to afford (*E*)-*N*-methyl-3-phenylprop-2-en-1-ylamine as a solution in ethanol. The solution was transferred to a flask equipped with a stirbar and cooled to -10 °C. Neat 4-nitrophenyl isocyanate (1.44g, 8.8 mmol) was added and the resulting solution and the reaction was slowly warmed to rt over the course of five h. The reaction mixture was then concentrated in vacuo and the crude product was purified by flash column chromatography to yield 430 mg (16%) of the title compound as

a white solid, mp 120–124 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.14 (d, J = 9.1 Hz, 2H), 7.55 (d, J = 9.3 Hz, 2H), 7.40 (d, J = 7.3 Hz, 2H), 7.34 (t, J = 7.3 Hz, 2H), 7.28 (t, J = 7.1 Hz, 1H), 6.92 (s, br, 1H), 6.60 (d, J = 16.0 Hz, 1H), 6.23 (dt, J = 5.9, 15.9 Hz, 1H), 4.17 (d, J = 5.9 Hz, 2H), 3.10 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.5, 145.4, 142.4, 135.9, 132.8, 128.7, 128.2, 126.5, 125.1, 123.9, 118.4, 51.2, 34.8; IR (film) 1659 cm⁻¹. MS (CI) 312.1353 (312.1343 calcd for C₁₇H₁₇N₃O₃, M + H⁺).


General procedure for asymmetric Pd-catalyzed carboamination reactions of *N*-allylurea derivatives. A flame-dried Schlenk tube equipped with a stirbar was cooled under a stream of nitrogen and then charged with Pd₂(dba)₃ (2 mol %), (*S*)-Siphos-PE (6 mol %), the urea substrate (1.0 equiv), and NaO^fBu (2.0 equiv). The flask was purged with N₂, then the aryl or alkenyl halide (2.0 equiv), the additive (H₂O, 2.0 equiv; or TFA, 40 mol % if needed) and xylenes (0.20 M, for reactions at 120 °C) or toluene (0.20 M, for reactions at 90 °C) were added. The resulting mixture was heated to 90 °C or 120 °C with stirring until the starting material had been consumed as judged by TLC analysis. The reaction mixture was then cooled to rt, saturated aqueous ammonium chloride (6mL/mmol substrate) was added, and the mixture was transferred to a separatory funnel. The mixture was extracted with ethyl acetate (3 x 5 mL) then the combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel.

(-)-(4S)-3-{4-[Benzyl(methyl)amino]phenyl}-4-[4-(tert-butyl)benzyl]-1-

methylimidazolidin-2-one (2a). The general procedure was employed for the coupling of 1-allyl-3-{4-[benzyl(methyl)amino]phenyl}-1-methylurea (0.10 mmol, 30.9 mg) and 4-bromo-*tert*-butylbenze (0.20 mmol, 42.6 mg), using a catalyst composed of $Pd_2(dba)_3$ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C, and a reaction time of 12 h. This procedure afforded the title compound (28.7 mg, 65%) as an orange oil: $[\alpha]^{23}_D$ –23.2 (*c* 0.68, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.34–7.23 (m, 9H), 7.05 (d, J = 8.2 Hz, 2H), 6.77 (d, J = 9.0 Hz, 2H), 4.52 (s, 2H), 4.28–4.20 (m, 1H), 3.30 (app. t, J = 8.6 Hz, 1H), 3.12 (dd, J = 6.1, 8.8 Hz, 1H), 3.06 (dd, J = 3.3, 13.7 Hz, 1H), 3.00 (s, 3H), 2.79 (s, 3H) 2.58 (dd, J = 10.0, 13.5 Hz, 1H), 1.30 (s, 9H); ¹³C NMR (125 MHz, CDCl₃); 159.5, 149.6, 147.3, 139.0, 133.8, 128.8, 128.6, 128.2, 126.9, 126.8, 125.5, 124.5, 112.9, 57.0, 55.9, 50.1, 38.7, 38.0, 34.4, 31.4, 31.3; IR (film) 1704 cm⁻¹; MS (CI) 442.2866 (442.2859 calcd for $C_{29}H_{35}N_3O$, M + H⁺). The enantiopurity was determined to be 73% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.50 mL/min, λ 198 nm, RT= 6.1 and 9.2 min).

(-)-(4S)-4-[4-(tert-Butyl)benzyl]-3-(4-methoxyphenyl)-1-methylimidazolidin-2-one

(2b). The general procedure was employed for the coupling of 1-allyl-3-(4-methoxyphenyl)-1-methylurea (0.10 mmol, 22.1 mg) and 4-bromo-*tert*-butylbenze (0.20 mmol, 42.6 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C, and a reaction time of 12 h. This procedure afforded the title compound (33.0 mg, 93%) as an orange oil: $[α]^{23}_D$ –10.1 (c 0.76, CH_2Cl_2); ¹H NMR (400 MHz, $CDCl_3$) δ 7.38 (d, J = 9.0 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 7.06 (d, J = 8.3 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 4.37–4.29 (m, 1H), 3.82 (s, 3H), 3.36 (app. t, J = 8.7 Hz, 1H), 3.17 (dd, J = 5.9, 9.2 Hz, 1H), 3.05 (dd, J = 3.7, 13.7 Hz, 1H), 2.81 (s, 3H), 2.62 (dd, J = 9.8, 13.7 Hz, 1H), 1.31 (s, 9H); ¹³C NMR (100 MHz, $CDCl_3$) 159.0, 156.4, 149.6, 133.5, 131.8, 128.8, 125.5, 123.8, 114.3, 55.5, 55.4, 49.8, 37.8, 34.4, 31.3, 31.2; IR (film) 1700 cm⁻¹; MS (CI) 353.2232 (353.2224 calcd for $C_{22}H_{28}N_2O_2$, M + H⁺). The enantiopurity was determined to be 79% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.50 mL/min, λ 198 nm, RT= 5.3 and 8.1 min).



(-)-(4S)-4-[4-(tert-Butyl)benzyl]-1-methyl-3-phenylimidazolidin-2-one (2c). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-phenylurea (0.10 mmol, 17.6 mg) and 4-bromo-tert-butylbenze (0.20 mmol, 42.6 mg) using a catalyst composed of Pd₂(dba)₃ (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C and a reaction time of 12 h. This procedure afforded the title compound (29.0 mg, 90%) as white solid, mp 67-70 °C: $[\alpha]^{23}_D$ -19.4 (c 0.55, CH_2Cl_2); ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 8.6 Hz, 2H), 7.37 (t, J = 7.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.12–7.06 (m, 3H), 4.48–4.40 (m, 1H), 3.37 (app. t, J = 8.6 Hz, 1H), 3.20 (dd, J = 4.9, 8.4 Hz, 1H), 3.11 (dd, J = 3.3, 13.8 Hz, 1H), 2.81 (s, 3H), 2.64 $(dd, J = 9.8, 13.8 \text{ Hz}, 1H), 1.30 (s, 9H); ^{13}C NMR (100 MHz, CDCl₃) 158.3, 149.7, 138.9,$ 133.5, 129.0, 128.8, 125.6, 123.4, 120.7, 54.4, 49.4, 37.5, 34.4, 31.3, 31.0; IR (film) 1707 cm $^{\text{-1}}$; MS (CI) 323.2125 (323.2118 calcd for $C_{21}H_{26}N_2O$, M + H $^{\text{+}}$). The enantiopurity was determined to be 78% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 8% IPA/Hexanes, 1.0 mL/min, λ 198 nm, RT= 9.5 and 10.1 min).

(-)-(4S)-3-(4-Bromophenyl)-4-[4-(tert-butyl)benzyl]-1-methylimidazolidin-2-one

(2d). The general procedure was employed for the coupling of 1-allyl-3-(4-bromophenyl)-1-methylurea (0.10 mmol, 26.9 mg) and 4-bromo-*tert*-butylbenze (0.20 mmol, 42.6 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C and a reaction time of 12 h. This procedure afforded the title compound (18.0 mg, 45%) as an orange oil: $[\alpha]^{23}_D$ –41.6 (c 0.42, CH_2CI_2); ¹H NMR (500 MHz, $CDCI_3$) δ 7.49–7.43 (m, 4H), 7.32 (d, J = 8.3 Hz, 2H), 7.07 (d, J = 8.1 Hz, 2H), 4.44–4.38 (m, 1H), 3.39 (app. t, J = 8.8 Hz, 1H), 3.22 (dd, J = 4.6, 9.0 Hz, 1H), 3.07 (dd, J = 3.7, 13.8 Hz, 1H), 2.82 (s, 3H), 2.66 (dd, J = 9.5, 13.8 Hz, 1H), 1.32 (s, 9H); ¹³C NMR (100 MHz, $CDCI_3$) 157.9, 150.0, 138.1, 133.3, 131.9, 128.8, 125.6, 121.9, 116.0, 54.2, 49.2, 37.4, 34.3, 31.3, 31.9; IR (film) 1708 cm⁻¹; MS (CI) 401.1230 (401.1223 calcd for $C_{21}H_{25}BrN_2O$, M + H⁺). The enantiopurity was determined to be 83% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.50 mL/min, λ 198 nm, RT= 4.3 and 6.0 min).

(-)-(5S)-4-{5-[4-(tert-Butyl)benzyl]-3-methyl-2-oxoimidazolidin-1-yl}benzonitrile

(2e): The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 4-bromo-*tert*-butylbenze (0.20 mmol, 42.6 mg) using a catalyst composed of Pd₂(dba)₃ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded the title compound (30.2 mg, 87%) as a light orange solid, mp 108–113 °C: [α]²³_D –73.6 (*c* 0.91, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) $\bar{\delta}$ 7.75 (d, J = 9.0 Hz, 2H), 7.63 (d, J = 9.0 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 4.50 (m, 1H), 3.46 (app. t, J = 8.8 Hz, 1H), 3.28 (dd, J = 3.5, 9.2 Hz, 1H), 3.10 (dd, J = 3.5, 14.1 Hz, 1H), 2.83 (s, 3H) 2.73 (dd, J = 9.2, 14.0 Hz, 1H), 1.32 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) $\bar{\delta}$ 156.9, 150.2, 143.2, 133.1, 132.6, 128.8, 125.7, 119.2, 118.5, 105.0, 53.6, 48.7, 37.3, 34.5, 31.3, 30.8; IR (film) 1712 cm⁻¹; MS (CI) 348.2082 (348.2070 calcd for C₂₂H₂₅N₃O, M + H⁺). The enantiopurity was determined to be 86% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 5.4 and 8.6 min).

(-)-(4S)-4-[4-(tert-Butyl)benzyl]-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2f)

The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromo-tert-butylbenzene (0.40 mmol, 85.2 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (59.6 mg, 81%) and 91% ee as a bright yellow solid, mp 115–118 °C: $[\alpha]^{23}_D$ –102.3 (*c* 1.49, CH_2CI_2); ¹H NMR (400 MHz, $CDCI_3$) δ 8.22 (d, J = 9.2 Hz, 2H), 7.78 (d, J = 9.4 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.9 (d, J = 8.2 Hz, 2H), 4.56–4.49 (m, 1H), 3.48 (app. t, J = 9.0 Hz, 1H), 3.29 (dd, J = 3.0, 9.3 Hz, 1H), 3.11 (dd, J = 3.5, 13.8 Hz, 1H), 2.83 (s, 3H), 2.75 (dd, J = 9.0, 13.9 Hz, 1H); ¹³C NMR (100 MHz, $CDCI_3$) δ 156.7, 150.3, 145.2, 141.9, 132.5, 128.8, 125.8, 125.0, 117.7, 53.7, 48.6, 37.3, 34.5, 31.3, 30.8; IR (film) 1717 cm⁻¹. MS (CI) 368.1968 (368.1969 calcd for $C_{21}H_{25}N_3O_3$, M + H⁺). The enantiopurity was determined to be 92% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.50 mL/min, λ 198 nm, RT= 6.1 and 9.4 min).

(-)-(4S)-4-[4-(*tert*-Butyl)benzyl]-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (X).

The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.10 mmol, 23.5 mg) and 4-iodo-*tert*-butylbenzene (0.20 mmol, 52.0

mg) using a catalyst composed of Pd₂(dba)₃ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (19.0 mg, 60%) as a bright yellow solid. This material contained ca 35% of an inseparable unidentified regioisomer. The enantiopurity was determined to be 47% ee by chiral HPLC analysis. Spectroscopic data were identical to those reported above.

(-)-(4S)-1-Methyl-3-(4-nitrophenyl)-4-[4-(trifluoromethyl)benzyl]imidazolidin-2-one

(2g). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromobenzotrifluoride (0.40 mmol, 90.0 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), H_2O (0.40 mmol, 7 μL) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (54.6 mg, 72%) as a bright yellow solid, mp 161–164 °C: $[α]^{23}_D$ –75.1 (*c* 11.5, CH_2CI_2); ¹H NMR (400 MHz, $CDCI_3$) δ 8.23 (d, J = 9.2 Hz, 2H), 7.78 (d, J = 9.3 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 4.64–4.58 (m, 1H), 3.51 (app. t, J = 9.0 Hz, 1H), 3.24 (dd, J = 3.1, 9.3 Hz, 1H), 3.17 (dd, J = 3.1, 9.3 Hz, 1H), 3.01 (dd, J = 8.6, 14.0 Hz, 1H), 2.80 (s, 3H); ¹³C NMR (100 MHz, $CDCI_3$) δ 156.5, 144.8, 142.1, 139.6, 129.6 (g,

65.2 Hz), 129.5, 125.8 (q, 3.81), 125.1, 123.9 (q, 272.0 Hz), 117.8, 53.2, 48.3, 37.5, 30.7; IR (film) 1708 cm⁻¹. MS (CI) 380.1211 (380.1217 calcd for $C_{18}H_{16}F_3N_3O_3$, M + H⁺). The enantiopurity was determined to be 95% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 9.3 and 16.8 min).

(-)-(4S)-1-Methyl-3-(4-nitrophenyl)-4-[3-(trifluoromethyl)benzyl]imidazolidin-2-one

(2h). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 3-bromobenzotrifluoride (0.40 mmol, 90.0 mg) using a catalyst composed of Pd₂(dba)₃ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), H₂O (0.40 mmol, 7 μL) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (53.1 mg, 70%) as a bright yellow solid, mp 145–148 °C: [α]²³_D –64.1 (*c* 1.16, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, J = 9.0 Hz, 2H), 7.77 (d, J = 9.0 Hz, 2H), 7.53 (d, J = 7.8 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.38 (s, 1H), 7.32 (d, J = 7.6 Hz, 1H), 4.65–4.58 (m, 1H), 3.53 (app. t, J = 9.0 Hz, 1H), 3.24 (dd, J = 2.7, 9.2 Hz, 1H), 3.15 (dd, J = 3.5, 14.1 Hz, 1H), 2.93 (dd, J = 8.4, 14.0 Hz, 1H), 2.79 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 156.5, 144.9, 142.1, 136.1, 132.7, 131.2 (q, J = 32.4 Hz), 129.4, 125.8 (q, J = 3.8 Hz), 123.9 (q, J = 271.8 Hz), 117.8, 53.1, 48.4, 37.6, 30.7; IR

(film) 1714 cm⁻¹. MS (CI) 380.1224 (380.1217 calcd for $C_{18}H_{16}F_3N_3O_3$, M + H⁺). The enantiopurity was determined to be 88% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 7.7 and 13.0 min).

(-)-(4S)-1-Methyl-3-(4-nitrophenyl)-4-[2-(trifluoromethyl)benzyl]imidazolidin-2-one

(2i). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 2-bromobenzotrifluoride (0.40 mmol, 90.0 mg), using a catalyst composed of $Pd_2(dba)_3$ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), H_2O (0.40 mmol, 7 μL) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (42.5 mg, 56%) as a bright yellow solid, mp 70–73 °C: $[\alpha]^{23}_D$ –98.7 (*c* 0.72, CH_2CI_2); ¹H NMR (400 MHz, $CDCI_3$) δ 8.14 (d, J = 9.0 Hz, 2H), 7.72–7.64 (m, 3H), 7.44 (t, J = 7.4 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 4.72–4.64 (m, 1H), 3.43 (app. t, J = 9.0 Hz, 1H), 3.36 (dd, J = 5.1, 14.4 Hz, 1H), 3.20 (dd, J = 2.0, 9.3 Hz, 1H), 2.96 (dd, J = 9.0, 14.3 Hz, 1H), 2.87 (s, 3H); ¹³C NMR (100 MHz, $CDCI_3$) δ 156.7, 145.1, 142.0, 134.4, 132.1, 129.2 (q, J = 30.0 Hz), 127.5, 126.6 (q, J = 5.7 Hz), 124.8, 124.4 (q, J = 272.3 Hz), 118.0, 53.1, 48.3, 35.0, 30.9 (one peak is missing due to incidental equivalence); IR (film) 1722 cm⁻¹. MS (CI) 380.1226 (380.1217 calcd for $C_{18}H_{16}F_3N_3O_3$, M + H⁺). The

enantiopurity was determined to be 83% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 7.9 and 12.5 min).

(-)-(4S)-4-(4-Benzoylbenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2j). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromobenzophenone (0.40 mmol, 104.4 mg) using a catalyst composed of Pd₂(dba)₃ (0.004 mmol, 3.7 mg) and (S)-Siphos-PE (0.012 mmol 6.1 mg), H₂O (0.40 mmol, 7 µL) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (68.1 mg, 82%) as a bright yellow solid, mp 115–118 °C: $[\alpha]^{23}_D$ –53.7 (c 0.97, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, J = 9.3 Hz, 2H), 7.80–7.72 (m, 6H), 7.57 (t, J = 7.4Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 4.65–4.58 (m, 1H), 3.50 (app. t, J = 9.0 Hz, 1H), 3.26 (dd, J = 3.1, 9.2 Hz, 1H), 3.18 (dd, J = 3.5, 14.0 Hz, 1H), 2.91 (dd, J = 8.8, 13.9 Hz, 1H), 2.80 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 196.1, 156.6, 145.0, 142.1, 140.3, 137.3, 136.6, 132.6, 130.6, 130.0, 129.2, 128.4, 125.1, 117.8, 53.2, 48.4, 37.8, 34.4, 30.8; IR (film) 1715, 1657 cm⁻¹. MS (CI) 416.1620 (416.1605 calcd for $C_{24}H_{21}N_3O_4$, M + H⁺). The enantiopurity was determined to be 86% ee by chiral HPLC analysis (ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 39.0 and 54.9 min.)

(-)-(4S)-4-(4-Fluorobenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2k). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromofluorobenzene (0.40 mmol, 70.0 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), H_2O (0.40 mmol, 7 μ L) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (43.0 mg, 65%) as a bright yellow solid, mp 153–157 °C: $[\alpha]^{23}_D$ –75.4 (*c* 1.10, CH_2CI_2); ¹H NMR (400 MHz, $CDCI_3$) δ 8.22 (d, J = 9.3 Hz, 2H), 7.88 (d, J = 9.3 Hz, 2H), 7.14–7.08 (m, 2H), 7.01 (app. t, J = 8.6 Hz, 2H), 4.58–4.51 (m, 1H), 3.49 (app. t, J = 9.0 Hz, 1H), 3.24 (dd, J = 3.1, 9.2 Hz, 1H), 3.06 (dd, J = 3.3, 14.0 Hz, 1H), 2.86–2.75 (m, 1H), 2.77 (s, 3H); ¹³C NMR (100 MHz, $CDCI_3$) δ 162.1 (d, J = 245.0 Hz), 156.6 145.0, 142.0, 131.1 (d, J = 3.5 Hz), 130.7 (d, J = 8.0 Hz), 125.1, 117.7, 115.8 (d, J = 21.3 Hz), 53.4, 48.2, 36.8, 30.7; IR (film) 1717 cm⁻¹. MS (CI) 330.1258 (330.1248 calcd for $C_{17}H_{16}FN_3O_3$, M + H⁺). The enantiopurity was determined to be 94% ee by chiral HPLC

analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 12.0 and 22.7 min).

(-)-(4S)-4-(4-Chlorobenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2I). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromochlorobenzene (0.40 mmol, 76.6 mg) using a catalyst composed of Pd₂(dba)₃ (0.004 mmol, 3.7 mg) and (S)-Siphos-PE (0.012 mmol 6.1 mg), H₂O (0.40 mmol, 7 µL) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (51.2 mg, 74%) as a bright vellow solid, mp 144–147 °C: $[\alpha]^{23}$ _D –72.9 (c 0.81, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.24 (d, J = 9.3 Hz, 2H), 7.78 (d, J = 9.3 Hz, 2H), 7.30 (d, J =8.3 Hz, 2H), 7.08 (d, J = 8.2 Hz, 2H), 4.57–4.50 (m, 1H), 3.48 (app. t, J = 9.0 Hz, 1H), 3.23 (dd, J = 3.1, 9.1 Hz, 1H), 3.08 (dd, J = 3.3, 14.0 Hz, 1H), 2.85–2.78 (m, 1H), 2.80 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.6, 144.9, 142.1, 133.8, 133.3, 130.5, 129.0, 125.1, 117.7, 53.3, 48.2, 37.0, 34.4; IR (film) 1716 cm⁻¹. MS (CI) 346.0956 (346.0953) calcd for C₁₇H₁₆ClN₃O₃, M + H⁺). The enantiopurity was determined to be 93% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 12.5 and 22.7 min).

(-)-(4S)-1-Methyl-4-(naphthalen-2-ylmethyl)-3-(4-nitrophenyl)imidazolidin-2-one

(2n). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 2-bromonaphthalene (0.40 mmol, 82.8 mg) using a catalyst composed of Pd₂(dba)₃ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (51.3 mg, 71%) as a bright yellow solid, mp 152–155 °C: [α]²³_D –116.7 (c 0.74, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, J = 9.1 Hz, 2H), 7.86–7.78 (m, 5H), 7.62 (s, 1H), 7.54–7.46 (m, 2H), 7.28 (d, J = 8.4 Hz, 1H), 4.68–4.61 (m, 1H), 3.46 (app. t, J = 9.2 Hz, 1H), 3.36–3.28 (m, 2H), 2.93 (dd, J = 9.3, 13.9 Hz, 1H), 2.81 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.7, 145.1, 142.0, 133.4, 133.0, 132.4, 128.7, 128.0, 127.7, 127.4, 126.9, 126.5, 126.0, 125.0, 117.8, 53.6, 48.5, 37.9, 30.8; IR (film) 1715 cm⁻¹. MS (CI) 362.1507 (362.1499 calcd for C₂₁H₁₉N₃O₃, M + H⁺). The enantiopurity was determined to be 89% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 9.4 and 17.4 min).

(-)-(4S)-1-Methyl-4-(4-morpholinobenzyl)-3-(4-nitrophenyl)imidazolidin-2-one (2o).

The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-(4-bromophenyl)morpholine (0.40 mmol, 96.8 mg) using a catalyst composed of Pd₂(dba)₃ (0.004 mmol, 3.7 mg) and (S)-Siphos-PE (0.012 mmol 6.1 mg), H₂O (0.40 mmol, 7 µL) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (63.4 mg, 80%) as a bright yellow solid, mp 125–129 °C: $[\alpha]^{23}_D$ –91.0 (c 0.97, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, J = 9.2 Hz, 2H), 7.78 (d, J = 9.2 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 4.53–4.45 (m, 1H), 3.90–3.81 (m, 4H), 3.46 (app. t, J = 8.9 Hz, 1H), 3.27 (dd, J = 2.9, 9.2 Hz, 1H), 3.18–3.08 (m, 4H), 3.04 (dd, J = 3.2, 14.1 Hz, 1H), 2.81 (s, 3H), 2.72 (dd, J = 8.8, 14.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 156.7, 150.4, 145.2, 141.9, 130.0, 126.6, 125.0, 117.7, 115.9, 67.1, 53.8, 49.3, 48.4, 36.8, 30.8; IR (film) 1717 cm⁻¹. MS (CI) 397.1872 (397.1870 calcd for $C_{21}H_{24}N_4O_4$ M+H⁺). The enantiopurity was determined to be 87% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 25.7 and 33.0 min).

(-)-(4S)-4-(4-Methoxybenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2p).

The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromoanisole (0.40 mmol, 74.8 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), TFA (0.08 mmol, 6 µL) as an additive, a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (55.3 mg, 81%) as a bright yellow solid, mp 110–113 °C: $[\alpha]^{23}_D$ –71.3 (*c* 0.98, CH_2Cl_2); ¹H NMR (400 MHz, $CDCl_3$) δ 8.22 (d, J = 9.2 Hz, 2H), 7.79 (d, J = 9.4 Hz, 2H), 7.06 (d, J = 8.5 Hz, 2H), 4.52–4.48 (m, 1H), 3.77 (s, 3H), 3.46 (app. t, J = 8.9 Hz, 1H), 3.26 (dd, J = 3.2, 9.0 Hz, 1H), 3.04 (dd, J = 3.4, 14.1 Hz, 1H), 2.79 (s, 3H), 2.74 (dd, J = 8.9, 14.1 Hz, 1H); ¹³C NMR (100 MHz, $CDCl_3$) δ 158.8, 156.7, 145.2, 141.9, 130.2, 127.3, 125.0, 117.7, 114.3, 55.3, 53.7, 48.3, 36.8, 30.8; IR (film) 1717 cm⁻¹. MS (CI) 342.1457 (342.1448 calcd for $C_{18}H_{19}N_3O_4$, M + H⁺). The enantiopurity was determined to be 90% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 14.1 and 25.9 min.)

(-)-(4S)-4-(3-Methoxybenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2q).

The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (0.20 mmol, 47.0 mg) and 3-bromoanisole (0.40 mmol, 74.8 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.004 mmol, 3.7 mg) and (*S*)-Siphos-PE (0.012 mmol 6.1 mg), a reaction temperature of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (51.2 mg, 75%) as a bright yellow solid, mp 110–114 °C: $[\alpha]^{23}_D$ –94.2 (c 0.73, CH_2CI_2); ¹H NMR (400 MHz, $CDCI_3$) δ 8.20 (d, J = 9.1 Hz, 2H), 7.77 (d, J = 9.3 Hz, 2H), 7.23 (t, J = 8.0 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 7.6 Hz, 1H), 6.65 (s, 1H), 4.56–4.48 (m, 1H), 3.76 (s, 1H), 3.44 (app. t, J = 9.0 Hz, 1H), 3.26 (dd, J = 2.9, 9.2 Hz, 1H), 3.08 (dd, J = 3.3, 13.9 Hz, 1H), 2.79 (s, 3H), 2.73 (dd, J = 9.0, 13.9 Hz, 1H); ¹³C NMR (100 MHz, $CDCI_3$) δ 159.9, 156.7, 145.1, 141.9, 137.1, 129.9, 125.0, 121.4, 117.6, 115.4, 112.0, 55.2, 53.5, 48.4, 37.7, 30.8; IR (film) 1716 cm⁻¹. MS (CI) 342.1461 (342.1448 calcd for $C_{18}H_{19}N_3O_4$, M + H*). The enantiopurity was determined to be 83% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 12.6 and 19.6 min).

(+)-(E,5S)-4-(3-Methyl-2-oxo-5-(3-(trimethylsilyl)allyl)imidazolidin-1-yl)benzonitrile

(2r). The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 2-bromovinyltrimethylsilane (0.20 mmol, 35.8 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded the title compound (20.0 mg, 64%) as a light orange solid, mp 130–133 °C: [α]²³_D +6.4 (c 0.50, CH_2CI_2); ¹H NMR (400 MHz, $CDCI_3$) δ 7.66 (d, J = 9.0 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 5.87 (dt, J = 6.2, 18.5 Hz, 1H), 5.76 (d, J = 18.7 Hz, 1H), 4.35 (m, 1H), 3.56 (app. t, J = 9.0 Hz, 1H), 3.23 (dd, J = 3.4, 9.1 Hz, 1H), 2.88 (s, 3H) 2.53 (m, 1H), 2.38 (m, 1H) 0.04 (s, 9H); ¹³C NMR (100 MHz, $CDCI_3$) δ 156.6, 143.1, 138.8, 136.5, 133.0, 127.5, 119.1, 118.6, 105.0, 51.6, 48.8, 38.9, 30.8, –1.4; IR (film) 1702 cm⁻¹; MS (CI) 314.1685 (314.1683 calcd for $C_{17}H_{23}N_3OSi$, M + H⁺). The enantiopurity was determined to be 86% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 200 nm, RT= 3.9 and 5.1 min).

(-)-(5S)-4-{3-Methyl-2-oxo-5-[4-(trifluoromethyl)benzyl]imidazolidin-1-

yl}benzonitrile (2s). The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 4-bromobenzotrifluoride (0.20 mmol, 45.0 mg), using a catalyst composed of Pd₂(dba)₃ (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), water (3.5 µL, 0.20 mmol) as an additive, a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded the title compound (20.7 mg, 58%) as a light orange solid, mp 120–124 °C: $[\alpha]^{23}_D$ –29.5 (c 1.12, CH_2Cl_2); ¹H NMR (700 MHz, CDCl₃) δ 7.72 (d, J= 8.9 Hz, 2H), 7.64 (d, J= 8.9 Hz, 2H), 7.57 (d, J= 8.0 Hz, 2H), 7.27 (d, J= 8.2 Hz, 2H), 4.56-4.52 (m, 1H), 3.46 (app. t, J= 9.0 Hz, 1H), 3.20 (dd, J= 3.4, 9.0 Hz, 1H), 3.13 (dd, J= 3.3, 14.1 Hz, 1H), 2.97 (dd, J= 8.7, 14.0 Hz, 1H), 2.78 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.7, 142.9, 139.7, 133.2, 129.7 (g, 32.4 Hz), 129.6, 125.8(g, 3.8 Hz), 124.0 (g, 272.0 Hz), 119.1, 118.7, 105.5, 53.0, 48.4, 37.5, 30.7; IR (film) 1717 cm⁻¹; MS (CI) 360.1322 (360.1318 calcd for $C_{19}H_{16}F_3N_3O$, M + H⁺). The enantiopurity was determined to be 77% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 200nm, RT= 8.9 and 16.6 min).

(-)-5S-4-{3-Methyl-2-oxo-5-[4-(trifluoromethyl)benzyl]imidazolidin-1-

yl}benzonitrile. (2s): The general procedure was employed for the coupling of 1-allyl-3-

(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 4-iodobenzotrifluoride (0.20 mmol, 54.4 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), water (3.5 μ L, 0.20 mmol) as an additive, a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded the title compound (27.9 mg, 77%) as a light orange oil. The enantiopurity was determined to be 80% ee by chiral HPLC analysis. Spectroscopic data were identical to those reported above.

(-)-(5S)-4-[3-Methyl-5-(4-methylbenzyl)-2-oxoimidazolidin-1-yl]benzonitrile (2t).

The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 4-bromotoluene (0.20 mmol, 34.2 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded the title compound (26.3 mg, 86%) as a light orange solid, mp 123–126 °C: $[\alpha]^{23}_D$ –55.7 (*c* 0.90, CH_2CI_2); ¹H NMR (500 MHz, $CDCI_3$) δ 7.77 (d, J = 9.0 Hz, 2H), 7.65 (d, J = 9.0 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 4.51–4.45 (m, 1H), 3.44 (app. t, J = 9.0 Hz, 1H), 3.26 (dd, J = 3.7, 9.2 Hz, 1H), 3.09 (dd, J = 3.4, 13.9 Hz, 1H), 2.82 (s, 3H) 2.72 (dd, J = 9.3, 13.9 Hz, 1H), 2.35 (s, 3H); ¹³C NMR (100 MHz,

CDCl₃) δ 156.9, 143.2, 136.9, 133.1, 132.5, 129.5, 129.0, 119.2, 118.5, 105.0, 53.5, 48.5, 37.2, 30.8, 21.0; IR (film) 1712 cm⁻¹; MS (CI) 306.1608 (306.1601 calcd for C₁₉H₁₉N₃O, M + H⁺). The enantiopurity was determined to be 85% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 5.4 and 8.6 min).

(-)-(5S)-4-[3-Methyl-5-(4-methylbenzyl)-2-oxoimidazolidin-1-yl]benzonitrile (2t):

The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 4-iodotoluene (0.20 mmol, 43.6 mg) using a catalyst composed of Pd₂(dba)₃ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded the title compound (27.2 mg, 89%) as a light orange oil. The enantiopurity was determined to be 73% ee by chiral HPLC analysis. Spectroscopic data were identical to those reported above.

(-)-(5S)-4-[5-(4-Methoxybenzyl)-3-methyl-2-oxoimidazolidin-1-yl]benzonitrile (2u).

The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 4-bromoanisole (0.20 mmol, 37.4 mg) using a catalyst composed of Pd₂(dba)₃ (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol,

3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded the title compound in (23.5 mg, 73%) as a light orange solid, mp 87–91 °C: $[\alpha]^{23}_D$ –52.9 (c 0.37, CH_2CI_2); ¹H NMR (400 MHz, $CDCI_3$) δ 7.74 (d, J = 9.0 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.06 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 4.46 (m, 1H), 3.79 (s, 3H), 3.43 (app. t, J = 9.0 Hz, 1H), 3.24 (dd, J = 3.3, 9.2 Hz, 1H), 3.04 (dd, J = 3.3, 14.0 Hz, 1H), 2.80 (s, 3H) 2.71 (dd, J = 9.0, 14.0 Hz, 1H); ¹³C NMR (100 MHz, $CDCI_3$) δ 158.4, 156.9, 143.2, 133.1, 130.2, 127.5, 118.5, 114.2, 105.0, 55.3, 53.5, 48.5, 36.7, 30.8; IR (film) 1711 cm⁻¹; MS (CI) 322.1548 (322.1550 calcd for $C_{19}H_{19}N_3O_2$, M + H⁺). The enantiopurity was determined to be 82% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 12.3 and 23.3 min).

(+)-(4S)-4-[4-(tert-Butyl)benzyl]-1,4-dimethyl-3-(4-nitrophenyl)imidazolidin-2-one

(5): The general procedure was employed for the coupling of 1-methyl-1-(2-methylallyl)-3-(4-nitrophenyl)urea (0.10 mmol, 24.9 mg) and 4-bromo-*tert*-butylbenzene (0.20 mmol, 42.6 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.002 mmol, 1.8 mg) and (*S*)-Siphos-PE (0.006 mmol, 3.0mg), a reaction temperature of 135 °C and a reaction time of 18 h. This procedure afforded the title compound (27.5 mg, 72%) as a yellow oil: $[\alpha]^{23}_D$ +70.2 (*c* 0.90, CH_2Cl_2); ¹H NMR (500 MHz, $CDCl_3$) δ 8.24 (d, J = 9.1 Hz, 2H), 7.54 (d, J = 9.1

Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 8.1 Hz, 2H), 3.49 (d, J = 9.1 Hz, 1H), 3.11 (d, J = 13.5 Hz, 1H), 3.23 (d, J = 8.8 Hz, 1H), 2.81 (d, J = 14.4 Hz, 1H), 2.74 (s, 3H), 1.47, (s, 3H), 1.29 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 158.0, 150.2, 144.5, 144.3, 132.3, 129.7, 125.6, 125.4, 124.4, 61.5, 56.3, 44.2, 34.5, 313, 30.6, 25.1; IR (film) 1716 cm⁻¹; MS (CI) 382.2133 (382.2125 calcd for $C_{22}H_{27}N_3O_3$, M + H⁺). The enantiopurity was determined to be 76% ee by chiral HPLC analysis (ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 7.5 and 7.9 min.)

Deuterium Labeling Studies:

(*Z*)-1-(3-*d*-Allyl)-1-methyl-3-(4-nitrophenyl)urea ((*Z*)-*d*-1f):² A flame dried round bottom flask equipped with a stir bar was cooled to rt under a stream of N_2 and charged with *N*-methylallylamine (5.0 mmol, 0.47 mL) and Et_2O (10 mL). The resulting solution was cooled to -42 °C using a CO_2/CH_3CN bath and stirred for 5 min. A solution of *n*-BuLi in hexanes (3.12 mL, 1.6 M, 5 mmol) was added slowly and the resulting mixture was stirred at -42 °C for 20 min. A solution of *t*-BuLi in pentane (3.50 mL, 1.4 M, 5 mmol) was added slowly and the resulting solution was stirred at -42 °C for 30 min. The CO_2/CH_3CN bath was replaced with a brine/ice bath and the reaction mixture was allowed to slowly warm to room temperature as the ice melted. The bath was removed and the mixture was stirred at rt for 1 h. The reaction mixture was then cooled to -78 °C and D_2O (1.8 mL, 100 mmol) from freshly cracked ampoules was slowly added. The

resulting mixture was warmed to rt and stirred overnight. The reaction mixture was cooled to 0 °C, quenched with H_2O (2 mL) and transferred to a separatory funnel. The mixture was extracted with Et_2O (2 x 5 mL) and the combined organic layers were dried over anhydrous Na_2SO_4 and filtered to afford a solution of (*Z*)-*N*-methyl-3-deuterioallylamine. The solution was transferred to a round bottom flask and cooled to 0 °C. A solution of 4-nitrophenylisocyanate (3.63 mmol, 596 mg) in CH_2Cl_2 (4 mL) was slowly added and the resulting mixture was warmed to rt and stirred for 5 h. The reaction mixture was then concentrated in vacuo and the crude product was purified by flash chromatography on silica gel to afford the title compound as (315 mg, 37% yield, >95% deuterium incorporation) a yellow solid, mp 80–83 °C. 1 H NMR (700 MHz, CDCl₃) δ 8.12 (d, J = 9.2 Hz, 2H), 7.51 (d, J = 9.2 Hz, 2H), 6.88 (s, br, 1H), 5.87–5.82 (m, 1H), 5.27 (d, J = 10.4 Hz, 1H), 3.98 (d, J = 5.3 Hz, 2H), 3.03 (s, 3H); 13 C NMR (175 MHz, CDCl₃) δ 154.5, 145.5, 142.3, 132.7, 125.0, 118.4, 117.2 (t, J = 23.8 Hz), 51.6, 34.8; IR (film) 1652 cm $^{-1}$. MS (Cl) 237.1099 (237.1092 calcd for $C_{11}H_{12}DN_3O_3$, M + H $^+$).

(-)-(1'R,4S)-1'-Deuterio-4-[4-(tert-butyl)benzyl]-1-methyl-3-(4-

nitrophenyl)imidazolidin-2-one (*d*-2f). The general procedure was employed for the coupling of (Z)-1-(3-d-allyl)-1-methyl-3-(4-nitrophenyl)urea (0.10 mmol, 23.6 mg) and 4-bromo-tert-butylbenzene (0.20 mmol, 42.6 mg) using a catalyst composed of Pd₂(dba)₃ (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol 3.0 mg), a reaction temperature

of 115 °C, and a reaction time of 18 h. This procedure afforded the title compound (32.1 mg, 85%) as a bright yellow solid, mp 110–113 °C, $[\alpha]^{23}$ _D –104 (c 1.00, CH₂Cl₂). This material was judged to be a 7:1 mixture of diastereomers by ¹H NMR analysis. Data are for the major isomer: ${}^{1}H$ NMR (700 MHz, CDCl₃) δ 8.22 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 8.9 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H), 4.54–4.50 (m, 1H), 3.48 (app. t, J = 8.7 Hz, 1H), 3.29 (dd, J = 2.6, 9.0 Hz, 1H), 3.09 (d, J = 3.2 Hz, 0.12 H), 2.74 (d, J = 9.0 Hz, 0.88 H), 2.83 (s, 3H), 1.30 (s, 9H); ¹³C NMR (175 MHz, CDCl₃) δ 156.7, 150.3, 145.2, 141.9, 132.4, 128.8, 125.8, 125.0, 117.7, 53.7, 48.6, 37.0 (t, J = 17.7 Hz), 34.5, 31.3, 30.8; IR (film) 1717 cm⁻¹. MS (CI) 369.2034 (369.2031 calcd for $C_{21}H_{24}DN_3O_3$, M + H⁺). The enantiopurity was determined to be 91% ee by chiral HPLC analysis (ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 6.3 and 9.5 min). The 1'R,4S relative stereochemistry was assigned on the basis of comparison of NMR data to those obtained for a sample of the title compound prepared using a catalyst composed of Pd₂(dba)₃ and DPE-Phos, which has previously been shown to effect the syn-carboamination of N-allylurea derivatives.¹

Discussion of Mechanism of Diastereomer Formation in the Reaction of (Z)-d-1f

The formation of the minor diastereomer in the reaction of (Z)-d-1f is likely due to competing β -hydride elimination processes, as we have previously observed in related tetrahydrofuran-forming reactions. ^[4] As shown below in Scheme S1, intermediate S1 (generated via oxidative addition of the aryl bromide to Pd(0) followed by deprotonation and transmetallation of the substrate) is formed from (Z)-d-1f. The syn-migratory insertion of the alkene into the Pd–N bond affords S2, which can undergo reductive

elimination to yield (1'R,4S)-d-2m. However, if this reductive elimination is relatively slow, S2 can undergo sigma bond rotation to S2a followed by syn- β -hydride elimination to afford S3. Reinsertion of the alkene into the Pd-H bond with the opposite regiochemistry provides S4, which can undergo sigma bond rotation to S4a. The syn- β -hydride elimination of H from S4a provides S5, which can undergo reinsertion of the alkene into the Pd-H bond to give S6. Reductive elimination from S6 then affords the minor diastereomer (1's,4s)-d-2m. No migration of the deuterium atom was observed, which is presumably a result of a kinetic isotope effect coupled with the statistical probability for β -H vs. β -D elimination.

Scheme S1. Mechanism of diastereomer formation in the reaction of (Z)-d-1f.

Deprotection of 2m and Assignment of Absolute Stereochemistry:

The absolute stereochemistry of the urea products was assigned by deprotection of **2m** (prepared via Pd-catalyzed carboamination of **1f**) to urea **6**. The optical rotation of **6** was of the same sign (–) as that of a separate sample of **6** prepared from L-phenylalanine as described below.

(-)-(4*S*)-4-Benzyl-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2m): The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (1.0 mmol, 235.2 mg) and bromobenzene (1.2 mmol, 188.4 mg) using a catalyst composed of $Pd_2(dba)_3$ (0.02 mmol, 18.0 mg) and (*S*)-Siphos-PE (0.06 mmol, 30.0 mg), a reaction temperature of 115 °C, and a reaction time of 18 h. This procedure afforded the title compound (256.9 mg, 83%) as a bright yellow solid, mp 125–128 °C: $[\alpha]^{23}_D$ –108.9 (*c* 1.22, CH_2CI_2); ¹H NMR (500 MHz, $CDCI_3$) $\bar{\delta}$ 8.24 (d, J = 9.3 Hz, 2H), 7.80 (d, J = 9.3 Hz, 2H), 7.33 (t, J = 6.9 Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.06 (d, J = 7.1 Hz, 2H), 4.58–4.52 (m, 1H), 3.47 (app. t, J = 8.8 Hz, 1H), 3.28 (dd, J = 2.9, 9.2 Hz, 1H), 3.14 (dd, J = 3.2, 13.9 Hz, 1H), 2.83–2.77 (m, 1H), 2.81 (s, 3H); ¹³C NMR (125 MHz, $CDCI_3$) $\bar{\delta}$ 156.7, 145.1, 142.0, 135.5, 129.2, 128.9, 127.3, 125.0, 117.7, 53.7, 48.4, 37.7, 30.8; IR (film) 1717 cm⁻¹; MS (CI) 312.1347 (312.1343 calcd for $C_{17}H_{17}N_3O_3$, M + H⁺). The

enantiopurity was determined to be 89% ee by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 10.5 and 17.1 min).

(-)-(4S)-4-Benzyl-1-methylimidazolidin-2-one (6). A glass microwave tube equipped with a stirbar was charged with 4-Benzyl-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (77.8 mg, 0.25 mmol,), 10% Pd/C (38.9 mg, 5% w/w Pd), ethyl acetate (2 mL) and methanol (1 mL). The tube was placed into a stainless steel bomb that was pressurized with H₂ to 50 psi and the reaction mixture was then stirred at rt for 12 h. The reaction vessel was then depressurized and the mixture was filtered through a pad of celite. The celite was washed with methanol (25 mL) and the combined organic solutions were concentrated in vacuo. The crude product from this reaction was dissolved in CH₂Cl₂ (0.7 mL) and transferred to a flame dried Schlenk tube equipped with a stir bar that had been cooled under a stream of nitrogen. Acetic anhydride (28 µL, 0.30 mmol) was added to the flask and the resulting solution was stirred at rt for 5 h. A solution of saturated aqueous Na₂CO₃ (5 mL) was added to the reaction vessel and the resulting mixture was transferred to a separatory funnel. The mixture was extracted with CH₂Cl₂ (3 x 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product from this reaction was placed into a round bottom flask equipped with a stir bar and dissolved in CH₃CN (3.5 mL) and


H₂O (0.70 mL). The mixture was cooled to 0 °C, stirred for 5 min, then ceric ammonium nitrate (1.13 mmol, 618.0 mg) was added in one portion. The resulting mixture was stirred at 0 °C for 25 min then saturated aqueous sodium sulfite (6 mL) was added. The mixture was transferred to a separatory funnel and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with saturated aqueous NaHCO₃ (5 mL) and brine (5 mL) then dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel to afford the title compound (41.6 mg, 88% overall yield) as a brown oil, [α]²³_D -27.0 (c 1.0, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.30 (t, J = 7.1 Hz, 2H), 7.24 (t, J =7.6 Hz, 1H), 7.17 (d, J = 7.1 Hz, 2H), 4.82–4.52 (s, br, 1H), 3.85 (m, 1H), 3.47 (app. t, J= 8.6 Hz, 1H), 3.13 (dd, J = 6.1, 8.8 Hz, 1H), 2.81 (app. d, J = 7.1 Hz, 2H), 2.76 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.9, 137.1, 129.0, 128.8, 126.9, 52.7, 51.1, 42.0, 30.5; IR (film) 1699 cm⁻¹; MS (CI) 191.1181 (191.1179 calcd for $C_{11}H_{14}N_2O$, M + H⁺). The enantiopurity was determined to be 85% ee by chiral HPLC analysis (Lux Amylose-2, 25 cm x 4.6 mm, 10% IPA/Hexanes, 1.0 mL/min, λ 210 nm, RT= 21.3 and 22.7 min).


(-)-(4S)-4-Benzyl-1-methylimidazolidin-2-one (6) A flame-dried round bottomed flask equipped with a stirbar was cooled under a stream of nitrogen and charged with (S)- N^1 -methyl-3-phenylpropane-1,2-diamine³ (100.0 mg, 0.60 mmol) and THF (1 mL). Solid CDI (90.0 mg, 0.56 mmol) was added and the resulting mixture was heated to 60 °C with stirring for 12 h. The reaction mixture was then cooled to rt and the solvent was


removed in vacuo. The product was purified by flash chromatography on silica gel to afford the title compound (32.0 mg, 30% yield); $[\alpha]^{23}_D$ –37.2 (c 0.90, CH_2CI_2). The spectroscopic properties of this compound were identical to that of compound **6.** The enantiopurity was determined to be 97% ee by chiral HPLC analysis (Lux Amylose-2, 25 cm x 4.6 mm, 10% IPA/Hexanes, 1.0 mL/min, λ 210 nm, RT= 21.3 and 22.7 min).


References


- [1] J.A. Fritz, J.P. Wolfe, *Tetrahedron* **2008**, *64*, 6838-6852.
- [2] J. Barluenga, F.J. Fananas, F. Foubelo, M. Yus, *J. Chem. Soc., Chem. Commun.* **1988**, 1135-1136.
- [3] J. Li, S. Luo, J. Cheng, J. Org. Chem. 2008, 1747-1750.
- [4] M. B. Hay, J. P. Wolfe, J. Am. Chem. Soc. 2005, 127, 16468–16476.


















































6/11/2012 18:12:31 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-II-120(I)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

: Admin : RAC-BAH-II-120(I)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID

Tray# Vail# : 1 Injection Volume Data File Name

: 1 uL : RAC-BAH-II-120(I)-ADH-15%IPA-1.5mI_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name

: Default.lcr : 6/7/2012 3:51:27 PM Data Acquired Data Processed : 6/7/2012 4:06:40 PM

t-Bu 2a

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-II-120(I)-ADH-15%IPA-1.5ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	5.893	69331412	2993485	49.525	50.433
2	8.839	70661842	2942080	50.475	49.567
Total		139993254	5935565	100 000	100 000

6/18/2012 14:30:15 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-187(I)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

: Admin : CHIRAL-BAH-III-187(I)-ADH-15%IPA-1.5ml_min Sample Name

Sample ID : <SAMPLE> Tray#

Vail# Injection Volume : 1 uL


Data File Name : CHIRAL-BAH-III-187(I)-ADH-15%IPA-1.5ml_min.lcd

: Cyclic Urea Method.lcm Method File Name

Batch File Name


Report File Name : Default.lor

Data Acquired : 6/13/2012 1:15:18 PM Data Processed : 6/13/2012 1:41:24 PM



<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-187(I)-ADH-15%IPA-1.5mI_min.lcd




PDA Multi 1/198nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	6.078	25236356	2043672	86.685	91.720
2	9.170	3876372	184483	13.315	8.280
Total		29112729	2228154	100.000	100.000





==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\B. HopkinsRAC-BAH-III-187(II)ADH-15%IPA-1.5mI_min.lcd

Acquired by Sample Name

: Admin : RAC-BAH-III-187(II)ADH-15%IPA-1.5ml_min

: <SAMPLE> Sample ID Tray# Vail#

Injection Volume : 1 uL

Data File Name : B. HopkinsRAC-BAH-III-187(II)ADH-15%IPA-1.5ml_min.lcd

Method File Name Cyclic Urea Method.lom

Batch File Name

Report File Name : Default.lor

Data Acquired 6/13/2012 3:29:57 PM Data Processed : 6/13/2012 4:15:50 PM

OMe 2b

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\B. HopkinsRAC-BAH-III-187(II)ADH-15%IPA-1.5mI_min.lcd mAU PDA Multi 1 1250-1000-750-500-250-10 min

PDA Multi 1/198nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	5.442	13776501	1286634	50.992	61.643
2	8.281	13240248	800590	49.008	38.357
Total		27016749	2087224	100.000	100.000

6/11/2012 18:19:32 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-II-34-ADH-15%IPA-1.5ml_min.lod: Admin

Acquired by

: CHIRAL-BAH-II-34-ADH-15%IPA-1.5ml_min Sample Name

Sample ID : <SAMPLE> Tray# Vail# Injection Volume

Data File Name : CHIRAL-BAH-II-34-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name : Default.lor

Data Acquired : 6/7/2012 10:29:07 AM


Data Processed : 6/7/2012 10:58:14 AM

OMe

2b

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-II-34-ADH-15%IPA-1.5ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

1 Dit Cit 17 citit 1 titit						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	5.262	24398002	1483328	89.839	91.144
	2	8.080	2759497	144122	10.161	8.856
	Total		27157499	1627450	100,000	100,000

6/11/2012 18:02:28 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-II-39-ADH-15%IPA-1.5ml_min.lcd

Acquired by : Admin

Sample Name : CHIRAL-BAH-II-39-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE> Tray#

Vail# Injection Volume


Data File Name : CHIRAL-BAH-II-39-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name : Default.lor

Data Acquired 6/11/2012 5:42:02 PM Data Processed : 6/11/2012 5:58:27 PM



2b (w/ (R)-Siphos-PE)


<Chromatogram>




PDA Multi 1/198nm 4nm

PeakTable

FDA CIII 198IIIII 4IIIII						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	5.416	20861745	1580948	37.536	41.085
	2	8.263	34716376	2267026	62.464	58.915
	Total		55578121	3847975	100 000	100.000





6/6/2012 17:11:57 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-II-56-ADH-8%IPA-1.0ml_min.lcd

Acquired by : Admin : RAC-BAH-II-58-ADH-8%IPA-1.0ml_min

Sample ID : <SAMPLE>
Tray# : 1
Vail # : 1

Vail # : 1 Injection Volume : 1 uL Data File Name : RAC

Data File Name : RAC-BAH-II-56-ADH-8%IPA-1.0ml_min.lod

Method File Name : Cyclic Urea Method.lcm


Batch File Name : Report File Name : Defau

O N t-Bu

2c

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-II-56-ADH-8%IPA-1.0ml_min.Icd



1 PDA Multi 1/198nm 4nm

PeakTable

Directi tyonin inni					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.369	17405197	757989	49.803	45.532
2	9.990	17542838	906760	50.197	54.468
Total	·	34948035	1664749	100 000	100 000

7/2/2012 14:40:29 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BAH-ii-57(2c).Icd

 Acquired by
 : Admin

 Sample Name
 : BAH-ii-57(2c)

 Sample ID
 : <SAMPLE>

 Tray#
 : 1

 Vail #
 : 1

 Injection Volume
 : 1 uL

Data File Name : BAH-ii-57(2c).lcd
Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name : Default.lor


Data Acquired : 7/2/2012 2:24:18 PM
Data Processed : 7/2/2012 2:37:21 PM

O N t-Bu

2c

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\BAH-ii-57(2c).lcd





1 PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.339	12187152	603290	89.156	88.053
2	9.965	1482275	81851	10.844	11.947
Total		13669427	685141	100.000	100.000





6/11/2012 18:57:56 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-II-123(I)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

Sample Name : RAC-BAH-II-123(I)-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE> Tray# Vail# Injection Volume


RAC-BAH-II-123(I)-ADH-15%IPA-1.5ml_min.lod Data File Name

Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name : Default.lo


6/8/2012 1:04:51 PM Data Acquired Data Processed : 6/8/2012 2:14:54 PM



2d

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-II-123(I)-ADH-15%IPA-1.5mI_min.lcd



PDA Multi 1/198nm 4nm

PeakTable

1 DA CHI 170HH THH					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	4.233	11825411	896990	52.927	55.214
2	6.018	10517470	727586	47.073	44.786
Total		22342881	1624577	100.000	100.000

7/2/2012 15:04:56 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BAH-ii-124(2d).Icd

 Acquired by
 : Admin

 Sample Name
 : BAH-ii-124(2d)

 Sample ID
 : <SAMPLE>

 Tray#
 : 1

Vail # :1
Injection Volume :1 uL

Data File Name : BAH-ii-124(2d).lcd Method File Name : Cyclic Urea Method.lcm

Batch File Name :


Report File Name : Default.lor

Data Acquired : 7/2/2012 2:45:57 PM
Data Processed : 7/2/2012 3:00:29 PM

O N t-Bu

2d


<Chromatogram>




1 PDA Multi 1/198nm 4nm

PeakTable

1 Dit Chi 170mii 1mii					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	4.366	9832740	1041963	91.726	93.193
2	6.149	886895	76108	8.274	6.807
Total		10719635	1118071	100,000	100.000





6/6/2012 16:34:40 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-II-154-ADH-15%IPA-1.5ml_min.lcd

Acquired by

: Admin : RAC-BAH-II-154-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID Tray# Vail# : 1 Injection Volume

Data File Name : RAC-BAH-II-154-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm


Batch File Name

Report File Name : Default.lor

6/6/2012 9:42:40 AM Data Acquired : 6/6/2012 10:43:59 AM Data Processed

2e

<Chromatogram>



PDA Multi 1/198nm 4nm

PeakTable

Biteir Donn inn						
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	5.632	20393415	1174136	50.274	56.635	
2	8.880	20170873	899024	49.726	43.365	
Total		40564288	2073160	100 000	100 000	

6/6/2012 18:09:38 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-II-161-ADH-15%IPA-1.5ml_min.lcd

Acquired by

: Admin : CHIRAL-BAH-II-181-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID Tray#

Vail# : 1 Injection Volume : 1 uL


Data File Name : CHIRAL-BAH-II-161-ADH-15%IPA-1.5ml_min.lcd

: Cyclic Urea Method.lom Method File Name

Batch File Name

Report File Name : Default.lor Data Acquired


: 6/6/2012 5:46:19 PM : 6/6/2012 6:04:50 PM Data Processed



2e

<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-II-161-ADH-15%IPA-1.5mI_min.Icd




PDA Multi 1/198nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	5.389	29555975	2828317	93.075	96.056
2	8.630	2199167	116134	6.925	3.944
Total		31755142	2944451	100.000	100.000





==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-76(I)-ADH-15%IPA-1.5mI_min.lcd

Acquired by Sample Name

: Admin : RAC-BAH-III-76(I)-ADH-15%IPA-1.5ml_min

: <SAMPLE> Sample ID Tray# : 1 Vail# : 1 Injection Volume : 1 uL


: RAC-BAH-III-76(I)-ADH-15%IPA-1.5ml_min.lcd : Cyclic Urea Method.lcm Data File Name

Method File Name

Batch File Name

Report File Name : Default.lor


: 1/30/2012 4:42:55 PM Data Acquired Data Processed : 1/30/2012 5:02:18 PM



 NO_2

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-76(I)-ADH-15%IPA-1.5ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

2 Dit Chi 13 Chin Thin						
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	5.901	10040148	1075460	51.781	64.206	
2	8.952	9349642	599557	48.219	35.794	
Total		19389790	1675017	100,000	100.000	

 NO_2

2f

`t-Bu

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-107(III)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

: Admin : CHIRAL-BAH-III-107(III)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID

Tray# Vail# Injection Volume

: 1 uL : CHIRAL-BAH-III-107(III)-ADH-15%IPA-1.5ml_min.lcd Data File Name

Method File Name : Cyclic Urea Method.lom


Batch File Name

Report File Name

: Default.lcr : 2/29/2012 5:57:39 PM Data Acquired Data Processed 2/29/2012 6:18:12 PM

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-107(III)-ADH-15%IPA-1.5mI_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	6.091	25616432	3013402	96.193	98.044
2	9.346	1013941	60112	3.807	1.956
Total		26630373	3073513	100,000	100.000

6/12/2012 18:41:57 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-89(IV)-ADH-15%IPA-1.50ml_min.lcd

Acquired by : Admin Sample Name : CHIRAL-BAH-III-89(IV)-ADH-15%IPA-1.50ml_min

Sample ID : <SAMPLE>
Tray# : 1

Vail # : 1 Injection Volume : 1 uL

Data File Name : CHIRAL-BAH-III-89(IV)-ADH-15%IPA-1.50ml_min.lod

Method File Name : Cyclic Urea Method.lcm

Batch File Name :


Report File Name : Default.lo

Data Acquired : 2/9/2012 6:08:03 PM Data Processed : 2/9/2012 6:39:31 PM

NO₂

2f (from 4-iodo-*tert*-butylbenzene)


<Chromatogram>




1 PDA Multi 1/198nm 4nm

PeakTable

1 Bit Citi 1 John Time					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	5.859	5434174	520821	73.536	81.277
2	8.884	1955621	119974	26.464	18.723
Total		7389795	640795	100.000	100.000





==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-85(I)-ADH-15%IPA-1.5ml_min.lcd : Admin

Acquired by : Admir

Sample Name : RAC-BAH-III-85(I)-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE>
Tray# : 1
Vail # : 1

Injection Volume : 1 uL

Data File Name : RAC-BAH-III-85(I)-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name : Default.lor

Data Acquired : 2/7/2012 10:56:40 AM Data Processed : 2/7/2012 11:32:49 AM

OND₂ OF₃

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-85(I)-ADH-15%IPA-1.5ml_min.lcd



1 PDA Multi 1/195nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.380	1508512	89477	50.198	65.373
2	16.662	1496638	47394	49.802	34.627
Total		3005150	136871	100.000	100.000

6/12/2012 15:56:05 1 / 1

==== Shimadzu LCsolution Analysis Report ====

 $\hbox{$C:$LabSolutions$Data$B. Hopkins$CHIRAL-BAH-III-90(I)-ADH-15\%IPA-1.50ml_min.lod: Admin: $CHIRAL-BAH-III-90(I)-ADH-15\%IPA-1.50ml_min.}$

Acquired by Sample Name

Sample ID : <SAMPLE> Tray# Vail# Injection Volume


Data File Name CHIRAL-BAH-III-90(I)-ADH-15%IPA-1.50ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name Default.lor

2/13/2012 4:04:52 PM Data Acquired Data Processed : 2/13/2012 4:35:11 PM



2g (without H₂O)

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-90(I)-ADH-15%IPA-1.50ml_min.lcd mAU PDA Multi 1 3000 2000-1000-10.0

1 PDA Multi 1/195nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	9.371	46823253	2916831	88.289	93.772
2	16.589	6211061	193724	11.711	6.228
Total		53034313	3110555	100.000	100.000

6/12/2012 15:49:38 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-90(II)-ADH-15%IPA-1.50mI_min.lcd

Acquired by Sample Name : Admin : CHIRAL-BAH-III-90(II)-ADH-15%IPA-1.50ml_min

: <SAMPLE> Sample ID Tray# Vail # : 1 : 1 Injection Volume : 1 uL


CHIRAL-BAH-III-90(II)-ADH-15%IPA-1.50ml_min.lcd Data File Name

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name Default.lor

2/13/2012 4:36:35 PM Data Acquired Data Processed 2/13/2012 5:03:59 PM



<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-90(II)-ADH-15%IPA-1.50ml_min.lcd




1 PDA Multi 1/195nm 4nm

PeakTable

1 DA CIII 195IIIII 4IIIII						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	9.344	51255265	2916724	97.507	98.710
	2	16.829	1310197	38112	2.493	1.290
	Total		52565462	2954836	100.000	100.000





C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-93(I)-ADH-15%IPA-1.5mI_min1.lcd

Acquired by Sample Name

: Admin : rao-BAH-III-93(I)-ADH-15%IPA-1.5ml_min

<SAMPLE> Sample ID : 1 Tray# Vail# : 1 Injection Volume : 1 uL

: rac-BAH-III-93(I)-ADH-15%IPA-1.5ml_min1.lcd Data File Name

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name Default.lor

2/16/2012 3:35:31 PM Data Acquired Data Processed 2/16/2012 4:40:03 PM NO_2

2h

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-93(I)-ADH-15%IPA-1.5ml_min1.lcd



1 PDA Multi 1/195nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.565	2958662	212608	50.414	63.420
2	12.836	2910088	122632	49.586	36.580
Total		5868750	335239	100.000	100.000

7/2/2012 17:01:35 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BBAH-iii-120-ii(2h).Icd

Acquired by Sample Name : Admin : BAH-iii-120-ii(2h) : <SAMPLE> Sample ID : 1


Tray# Vail # : 1 Injection Volume

: 1 uL : BBAH-iii-120-ii(2h).lcd Data File Name Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name


: Default.lcr : 7/2/2012 4:42:41 PM : 7/2/2012 4:59:16 PM Data Acquired Data Processed



2h

<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\BBAH-iii-120-ii(2h).lcd




PDA Multi 1/195nm 4nm

PeakTable

FDA CIII 195IIIII 4IIIII						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	7.819	39038134	2849387	94.088	96.900
	2	13.196	2452853	91156	5.912	3.100
	Total	· ·	41400087	2940543	100 000	100 000





C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-93(II)-ADH-15%IPA-1.5mI_min1.lcd

Acquired by

: Admin : rao-BAH-III-93(II)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID Tray# Vail# Injection Volume

: rao-BAH-III-93(II)-ADH-15%IPA-1.5ml_min1.lcd Data File Name

Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name Default.lor


: 2/16/2012 5:53:49 PM Data Acquired Data Processed : 2/16/2012 6:11:50 PM

NO_2 CF3

2i

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\rao-BAH-III-93(II)-ADH-15%IPA-1.5ml_min1.lcd



1 PDA Multi 1/195nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.500	10438937	778284	52.514	66.610
2	12.008	9439517	390144	47.486	33.390
Total		19878454	1168428	100.000	100.000

7/2/2012 15:47:45 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BAH-iii-125-ii(2i).Icd

Acquired by Sample Name : Admin : BAH-iii-125-ii(2i) : <SAMPLE> Sample ID

Tray# Vail # : 1 Injection Volume : 1 uL

: BAH-iii-125-ii(2i).lcd Data File Name : Cyclic Urea Method.lcm Method File Name

Batch File Name

Report File Name Data Acquired


: Default.lor : 7/2/2012 3:23:41 PM Data Processed : 7/2/2012 3:41:47 PM

NO_2

2i

<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\BAH-iii-125-ii(2i).lcd




1 PDA Multi 1/195nm 4nm

PeakTable

1 Dit Cit 155iiii 4iiii					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.709	19948380	1426731	91.476	95.096
2	12.429	1858926	73572	8.524	4.904
Total		21807306	1500302	100.000	100.000





 NO_2

6/18/2012 15:41:35 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-115-IV-ADH-15%IPA-1.5ml_min.lod: Admin

Acquired by Sample Name : RAC-BAH-III-115-IV-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE> Tray#

Vail# Injection Volume : 1 uL


Data File Name : RAC-BAH-III-115-IV-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name Report File Name : Default.lor

6/18/2012 2:11:20 PM Data Acquired Data Processed : 6/18/2012 3:21:23 PM

2j <Chromatogram>



PDA Multi 1/195nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	41.550	10651685	102441	50.245	56.903
2	57.915	10547826	77586	49.755	43.097
Total		21199511	180027	100.000	100.000

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-109(II)-ADH-15%IPA-1.5ml_min.lcd

Acquired by Sample Name

: Admin : CHIRAL-BAH-III-109(II)-ADH-15%IPA-1.5ml_min

: <SAMPLE> Sample ID Tray# Vail #

: 1 Injection Volume : 1 uL


Data File Name : CHIRAL-BAH-III-109(II)-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name : Default.lor

Data Acquired 3/4/2012 2:44:19 PM Data Processed : 3/4/2012 3:54:22 PM



<Chromatogram>


 $\label{lem:conditions} $$C:\abSolutions\Data\B.\ Hopkins\CHIRAL-BAH-III-109(II)-ADH-15\%IPA-1.5ml_min.Icd$$




PDA Ch1 195nm 4nm

1 DA CIII 195IIII 4IIII						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	38.962	35917342	463475	92.764	94.869
	2	54.868	2801554	25068	7.236	5.131
	Total		38718896	488543	100.000	100.000

PeakTable |





C:\LabSolutions\Data\B. Hopkins\rao-BAH-III-93(III)-ADH-15%IPA-1.5mI_min1.lcd

Acquired by

: Admin : rao-BAH-III-93(III)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID Tray# : 1 Vail#


Injection Volume Data File Name

: rao-BAH-III-93(III)-ADH-15%IPA-1.5ml_min1.Icd Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name : Default.lor

Data Acquired 2/16/2012 6:20:23 PM : 2/16/2012 6:50:06 PM Data Processed



<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-93(III)-ADH-15%IPA-1.5ml_min1.lcd



PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.491	15416348	765454	51.389	68.899
2	21.528	14582919	345526	48.611	31.101
Total		29999267	1110980	100.000	100.000

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-122-ADH-15%IPA-1.5ml_min.lcd: Admin: CHIRAL-BAH-III-122-ADH-15%IPA-1.5ml_min

Acquired by Sample Name Sample ID

: <SAMPLE> Tray# : 1

Vail# : 1 Injection Volume : 1 uL

: CHIRAL-BAH-III-122-ADH-15%IPA-1.5ml_min.lcd Data File Name

Method File Name

: Cyclic Urea Method.lom

Batch File Name Report File Name

: Default.lor : 3/19/2012 2:39:49 PM


Data Acquired Data Processed

: 3/19/2012 3:05:11 PM

 NO_2 2k

<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-122-ADH-15%IPA-1.5ml_min.lcd




PDA Multi 1/193nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %	
1	11.970	53026199	2203397	97.022	98.346	
2	22.716	1627748	37050	2.978	1.654	
Total		54653947	2240447	100 000	100 000	





 $\label{lab-solutions} C: LabSolutions \ Data \ B. \ Hopkins \ RAC-BAH-III-191(I)-ADH-15\% \ IPA-1.5ml_min.lod: Admin \ Admin$

Acquired by

Sample Name : RAC-BAH-III-191(I)-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE> Tray# Vail#

Injection Volume : 1 uL

Data File Name : RAC-BAH-III-191(I)-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name : Default.lor

Data Acquired : 6/15/2012 12:04:41 PM Data Processed : 6/15/2012 12:31:56 PM

NO_2 21

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-191(I)-ADH-15%IPA-1.5mI_min.lcd



PDA Multi 1/195nm 4nm

PeakTable

2011 0111 177 11111					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.534	8705719	329531	50.501	63.752
2	22.526	8532834	187365	49.499	36.248
Total		17238553	516896	100,000	100.000

7/2/2012 18:41:58 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BAH-iii-134-iii(2l).lcd

: Admin : BAH-iii-134-iii(2I) Acquired by Sample Name : <SAMPLE> Sample ID Tray# : 1


Vail# : 1 Injection Volume : 1 uL

Data File Name BAH-iii-134-iii(2I).lcd Method File Name Batch File Name : Cyclic Urea Method.lcm

: Default.lar : 7/2/2012 5:50:23 PM : 7/2/2012 6:15:34 PM Report File Name Data Acquired Data Processed

NO_2 21


<Chromatogram>




1 PDA Multi 1/195nm 4nm

PeakTable

	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	12.619	73124560	2850512	96.311	97.808
	2	22.854	2801215	63874	3.689	2.192
	Total		75925775	2914386	100.000	100.000





C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-176(I)-ADH-15%IPA-1.5mI_min.lcd

Acquired by : Admin Sample Name : RAC-B

ne : RAC-BAH-III-176(I)-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE>
Tray# : 1


Vail # : 1 Injection Volume : 1 uL

Data File Name : RAC-BAH-III-176(I)-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm


Batch File Name : Report File Name : Default.lor

Data Acquired : 6/6/2012 11:25:16 AM Data Processed : 6/6/2012 11:59:03 AM



2m

<Chromatogram>



DDA	Ch1	100	Anno

FDA CIII 190IIII 4IIIII						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	10.500	15629577	761653	50.858	62.013
	2	17.000	15102321	466566	49.142	37.987
	Total		30731898	1228219	100.000	100.000

6/18/2012 13:31:29 1 / 1

==== Shimadzu LCsolution Analysis Report ====

 $C: LabSolutions \\ \label{label} Data \\ B. Hopkins \\ \c HIRAL-BAH-III-176 \\ \c III-ADH-15\% \\ \c PA-1.5ml_min.lod: Admin$

Acquired by : Admir

Sample Name : CHIRAL-BAH-III-176(II)-ADH-15%IPA-1.5ml_min

 Sample ID
 : <SAMPLE>

 Tray#
 : 1

 Vail #
 : 1

 Injection Volume
 : 1 uL


Data File Name : CHIRAL-BAH-III-176(II)-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name :


Report File Name : Default.lor

Data Acquired : 6/8/2012 1:05:47 PM Data Processed : 6/8/2012 1:26:02 PM



<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-176(II)-ADH-15%IPA-1.5ml_min.lcd




1 PDA Multi 1/198nm 4nm

PeakTable

		- 1	Juli I dolo		
PDA Ch1 1	98nm 4nm				
Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.492	23025310	1352429	94.456	96.859
2	17.058	1351374	43853	5.544	3.141
Total		24376684	1396282	100.000	100.000





C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-191-2-ADH-15%IPA-1.5ml_min.lcd

: Admin : RAC-BAH-III-191-2-ADH-15%IPA-1.5ml_min Acquired by Sample Name

: <SAMPLE> Sample ID Tray# Vail#

Injection Volume : 1 uL


Data File Name : RAC-BAH-III-191-2-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name : Default.lor

Data Acquired : 6/18/2012 3:36:16 PM Data Processed : 6/18/2012 4:32:15 PM



<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-191-2-ADH-15%IPA-1.5ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	12.675	15142562	594519	50.069	62.929			
2	22.095	15100795	350226	49.931	37.071			
Total		30243357	944745	100 000	100.000			

7/2/2012 19:30:13 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BAH-iii-147-2n.lcd


Acquired by : Admin
Sample Name : BAH-iii-147-2n
Sample ID : <SAMPLE>
Tray# : 1
Vail # : 1

Injection Volume : 1 uL
Data File Name : BAH-iii-147-2n.lcd
Method File Name : Cyclic Urea Method.lcm

Batch File Name :


Report File Name : Default.lor

Data Acquired : 7/2/2012 7:01:39 PM
Data Processed : 7/2/2012 7:25:37 PM



<Chromatogram>


2n




1 PDA Multi 1/198nm 4nm

PeakTable

I DA CIII I	DA CIII 190iliii 4iliii				
Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.492	58028359	2986559	94.475	97.297
2	21.727	3393857	82984	5.525	2.703
Total		61422216	3069542	100 000	100 000





6/18/2012 14:09:41 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-89-3-ADH-15%IPA-1.5ml_min.lcd

Acquired by : Admi

Sample Name : RAC-BAH-III-89-3-ADH-15%IPA-1.5ml_min

 Sample ID
 : <SAMPLE>

 Tray#
 : 1

 Vail #
 : 1

 Injection Volume
 : 1 uL


Data File Name : RAC-BAH-III-89-3-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm


Batch File Name

Report File Name : Default.lcr Data Acquired : 6/18/2012 1:26:13 PM

Data Processed : 6/18/2012 2:06:51 PM



<Chromatogram> 20



1 PDA Multi 1/195nm 4nm

PeakTable

1 DA CIII 193IIII 4IIII						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	26.294	14715240	257577	50.432	57.239
	2	33.590	14463291	192428	49.568	42.761
	Total		29178532	450005	100.000	100.000

6/15/2012 17:37:12 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-108(IV)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

: Admin : CHIRAL-BAH-III-108(IV)-ADH-15%IPA-1.5ml_min Sample Name

Sample ID <SAMPLE> Tray# Vail#


Injection Volume : 1 uL Data File Name CHIRAL-BAH-III-108(IV)-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name Default.lor

Data Acquired 3/2/2012 2:24:04 PM Data Processed : 3/2/2012 2:59:29 PM



<Chromatogram>

20





1 PDA Multi 1/195nm 4nm

PeakTable

DDΔ Ch1 105nm 4nm

PDA Cn1 195mm 4mm						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	25.715	8058314	163227	93.720	95.363
	2	32.990	540006	7937	6.280	4.637
	Total		8598320	171164	100.000	100.000





 $\hbox{$C:$LabSolutions$Data$B. Hopkins$RAC-BAH-III-84(I)-ADH-15\%IPA-1.5mI_minTRY3.Iod: Admin}$

Acquired by : Adm

Sample Name : RAC-BAH-III-84(I)-ADH-15%IPA-1.5ml_minTRY3

Sample ID : <SAMPLE>
Tray# : 1
Vail # : 1

Injection Volume : 1 uL


Data File Name : RAC-BAH-III-84(I)-ADH-15%IPA-1.5ml_minTRY3.lcd

Method File Name : Cyclic Urea Method.lom

Batch File Name


Report File Name : Default.lor

Data Acquired : 2/6/2012 5:55:14 PM Data Processed : 2/6/2012 6:30:02 PM



<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-84(I)-ADH-15%IPA-1.5mI_minTRY3.lcd



1 PDA Multi 1/195nm 4nm

PeakTable

1 Dit Citi 175 min 1 min						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	13.610	12066213	532319	51.112	66.425
	2	24.552	11541063	269068	48.888	33.575
	Total		23607276	801386	100.000	100.000

6/12/2012 18:53:49 1 / 1

==== Shimadzu LCsolution Analysis Report ====

 $\hbox{C:$LabSolutions$Data$B. Hopkins$CHIRAL-BAH-III-104(II)-ADH-15\%IPA-1.0ml_min.Iod: Admin} \\$

Acquired by : Admin

Sample Name : CHIRAL-BAH-III-104(II)-ADH-15%IPA-1.0ml_min

Sample ID : <SAMPLE>
Tray# : 1
Vail # : 1


Injection Volume : 1 uL
Data File Name : CHIRAL-BAH-III-104(II)-ADH-15%IPA-1.0ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name :


Report File Name : Default.lor

Data Acquired : 2/24/2012 4:03:50 PM Data Processed : 2/24/2012 4:38:03 PM



<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-104(II)-ADH-15%IPA-1.0ml_min.lcd




1 PDA Multi 1/195nm 4nm

PeakTable

1 DA CIII 193IIII 4IIIII						
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	14.141	36769486	1952058	94.785	97.818
	2	25.892	2023005	43552	5.215	2.182
	Total		38702401	1005600	100 000	100 000





C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-93(IV)-ADH-15%IPA-1.5ml_min1.lcd

Acquired by : Admin

: rao-BAH-III-93(IV)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID Tray# Vail#

: 1 Injection Volume


: rac-BAH-III-93(IV)-ADH-15%IPA-1.5ml_min1.lcd Data File Name

Method File Name : Cyclic Urea Method.lcm

Batch File Name Report File Name : Default.lor

Data Acquired


: 2/16/2012 6:56:16 PM Data Processed : 2/16/2012 8:06:18 PM



2q

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-93(IV)-ADH-15%IPA-1.5mI_min1.lcd



1 PDA Multi 1/195nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.994	17954287	933121	51.641	63.876
2	18.691	16813544	527718	48.359	36.124
Tota	1	34767830	1460839	100.000	100.000

6/12/2012 19:12:36 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-126(II-ADH-15%IPA-1.5ml_min.lcd

Acquired by

: Admin : CHIRAL-BAH-III-128(II)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID Tray# Vail# Injection Volume


Data File Name : CHIRAL-BAH-III-126(II-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name : Default.lor


: 3/23/2012 3:25:19 PM Data Acquired Data Processed : 3/23/2012 3:52:33 PM



2q

<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-126(II-ADH-15%IPA-1.5ml_min.Icd




1 PDA Multi 1/195nm 4nm

PeakTable

I cuit I do l'						
	PDA Ch1 19:	5nm 4nm				
	Peak#	Ret. Time	Area	Height	Area %	Height %
	1	12.567	12963493	407430	91.720	93.694
	2	19.560	1170337	27423	8.280	6.306
	Total		14133829	434854	100.000	100.000





6/12/2012 19:19:43 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-21(I)-ADH-15%IPA-1.5ml_min.lcd

: Admin

Acquired by Sample Name : rao-BAH-III-21(I)-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE>

Tray# Vail# : 1 Injection Volume : 1 uL


Data File Name : rao-BAH-III-21(I)-ADH-15%IPA-1.5ml_min.lod

: Cyclic Urea Method.lom Method File Name

Batch File Name

Report File Name : Default.lor


Data Acquired : 6/10/2012 3:54:23 PM Data Processed : 6/10/2012 4:02:42 PM



2r

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\rac-BAH-III-21(I)-ADH-15%IPA-1.5mI_min.lcd



PDA Multi 1/200nm 4nm

PeakTable

PDA Ch1 200nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	3.890	2795759	361237	50.067	55.453
2	5.122	2788303	290187	49.933	44.547
Total		5584062	651424	100 000	100 000

6/12/2012 19:22:43 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\chiral-BAH-III-21(II)-ADH-15%IPA-1.5ml_min.lcd

: Admin : chiral-BAH-III-21(II)-ADH-15%IPA-1.5ml_min Acquired by Sample Name

Sample ID : <SAMPLE>

Tray# Vail# Injection Volume


: chiral-BAH-III-21(II)-ADH-15%IPA-1.5ml_min.lcd Data File Name Method File Name

: Cyclic Urea Method.lcm

Batch File Name

Report File Name


: Default.lcr : 6/10/2012 4:04:38 PM : 6/10/2012 4:18:18 PM Data Acquired Data Processed



2r

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\chiral-BAH-III-21(II)-ADH-15%IPA-1.5mI_min.lcd





1 PDA Multi 1/200nm 4nm

PeakTable

PDA Ch1 200nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	3.899	25522977	3087157	93.036	93.989
2	5.122	1910444	197454	6.964	6.011
Total		27433421	3284611	100.000	100.000





C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-145(I)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

: Admin : RAC-BAH-III-145(I)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID Tray# : 1

: 1 Vail# Injection Volume


: 1 uL : RAC-BAH-III-145(I)-ADH-15%IPA-1.5mI_min.lcd Data File Name


Method File Name : Cyclic Urea Method.lcm

Batch File Name Report File Name

: Default.lor 5/4/2012 1:35:10 PM Data Acquired : 5/4/2012 2:02:04 PM Data Processed

<Chromatogram>





PDA Multi 1/200nm 4nm

PeakTable

PDA Ch1 200nm 4nm								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	9.241	18721309	842315	49.835	65.899			
2	16.706	18845151	435870	50.165	34.101			
Total		37566460	1278185	100.000	100.000			

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-145(III)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

: Admin : CHIRAL-BAH-III-145(III)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID

Tray# Vail# : 1 Injection Volume


: CHIRAL-BAH-III-145(III)-ADH-15%IPA-1.5ml_min.lcd Data File Name

: Cyclic Urea Method.lcm Method File Name

Batch File Name

Report File Name

: Default.lor : 5/4/2012 2:33:09 PM Data Acquired Data Processed : 5/4/2012 2:52:53 PM



<Chromatogram>

mAU 1250-PDA Multi 1 1000-750-500-250-

15.0

17.5

20.0

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-145(III)-ADH-15%IPA-1.5mI_min.lcd

PeakTable

PDA Ch1 200nm 4nm

I DA CIII 200IIII 4IIIII								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	8.925	33083004	1188356	88.368	91.425			
2	16.552	4354750	111457	11.632	8.575			
Total		37437754	1299812	100.000	100.000			

12.5

CN

6/12/2012 19:47:17 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-148(II)-ADH-15%IPA-1.5mI_min.lcd

Acquired by

: Admin : CHIRAL-BAH-III-148(II)-ADH-15%IPA-1.5ml_min Sample Name

: <SAMPLE> Sample ID

Tray# Vail# : 1 Injection Volume

Data File Name : CHIRAL-BAH-III-146(II)-ADH-15%IPA-1.5ml_min.lcd


Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name : Default.lor

5/6/2012 12:05:35 PM Data Acquired Data Processed 5/6/2012 12:27:26 PM 2s (4-iodobenzotrifluoride)

<Chromatogram>





PDA Multi 1/200nm 4nm

PeakTable

PDA Ch1 200nm 4nm

1 Dit Chi 200mii 1mii								
Peak#	Ret. Time	Area	Height	Area %	Height %			
1	9.011	36905138	1281521	89.880	92.421			
2	16.807	4155151	105094	10.120	7.579			
Total		41060288	1386615	100.000	100.000			





C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-164-I-ADH-15%IPA-1.5ml_min.lcd

Acquired by Sample Name : Admin : RAC-BAH-III-164-I-ADH-15%IPA-1.5ml_min

Sample ID : <SAMPLE>
Tray# : 1
Vail # : 1

Vail # : 1 Injection Volume : 1 uL


Data File Name : RAC-BAH-III-164-I-ADH-15%IPA-1.5ml_min.lcd

Method File Name : Cyclic Urea Method.lom

Batch File Name


Report File Name : Default.lor

Data Acquired : 6/19/2012 2:18:36 PM Data Processed : 6/19/2012 2:36:22 PM



<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-164-I-ADH-15%IPA-1.5mI_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm									
	Peak#	Ret. Time	Area	Height	Area %	Height %			
	1	8.406	6452556	409002	49.490	63.221			
	2	14.579	6585639	237940	50.510	36.779			
	Total		13038195	646942	100 000	100 000			

7/1/2012 17:57:55 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-II-164(II)-ADH-15%IPA-1.50ml_min.lcd : Admin

Acquired by

: CHIRAL-BAH-II-164(II)-ADH-15%IPA-1.50ml_min Sample Name

Sample ID : <SAMPLE> Tray# Vail# Injection Volume


Data File Name CHIRAL-BAH-II-164(II)-ADH-15%IPA-1.50ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name Default.lor

6/27/2012 5:07:24 PM Data Acquired 6/27/2012 5:27:36 PM Data Processed



<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-II-164(II)-ADH-15%IPA-1.50ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm

Dirent from the						
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	8.260	46152171	2612300	92.314	95.337	
2	14.445	3842436	127773	7.686	4.663	
Total		49994607	2740073	100 000	100 000	

7/2/2012 18:50:24 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BAH-II-166-I-2t.lcd


Acquired by : Admin
Sample Name : BAH-II-166-I-2t
Sample ID : <SAMPLE>
Tray# :1
Vall # :1
Injection Volume :1 uL
Data File Name : BAH-II-166-I-2t.lod
Method File Name : Cycilic Urea Method Icm

 Batch File Name
 :

 Report File Name
 : Default.lcr


 Data Acquired
 : 7/2/2012 6:29:55 PM

 Data Processed
 : 7/2/2012 6:47:39 PM



2t (w/ 4-iodotoluene)

<Chromatogram>





1 PDA Multi 1/198nm 4nm

PeakTable

PDA Chl 198nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	8.273	16759962	837717	86.506	90.301
2	14.396	2614446	89977	13.494	9.699
Total		19374408	927694	100.000	100.000





2u

7/1/2012 18:36:32 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-8(I)-ADH-15%IPA-1.50ml_min.lcd

Acquired by

: Admin : RAC-BAH-III-8(I)-ADH-15%IPA-1.50ml_min Sample Name

: <SAMPLE> Sample ID

Tray# Vail # Injection Volume : 1 uL

: RAC-BAH-III-8(I)-ADH-15%IPA-1.50ml_min.lcd Data File Name

Method File Name : Cyclic Urea Method.lom


Batch File Name

Report File Name : Default.lor

Data Acquired : 7/1/2012 6:03:56 PM Data Processed : 7/1/2012 6:31:27 PM

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-8(I)-ADH-15%IPA-1.50ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	12.937	6228978	238054	50.256	64.861
2	24.640	6165434	128968	49.744	35.139
Total		12394413	367022	100,000	100,000

7/1/2012 19:06:04 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-8(II)-ADH-15%IPA-1.50ml_min.lcd: Admin: CHIRALBAH-III-8(II)-ADH-15%IPA-1.50ml_min

Acquired by

Sample Name

Sample ID : <SAMPLE>

Tray# Vail# : 1 Injection Volume

Data File Name : CHIRAL-BAH-III-8(II)-ADH-15%IPA-1.50ml_min.lcd

Method File Name : Cyclic Urea Method.lcm

Batch File Name Report File Name


Default.lor Data Acquired 7/1/2012 6:33:11 PM Data Processed : 7/1/2012 7:03:56 PM

ÒΜe 2u

CN

<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-8(II)-ADH-15%IPA-1.50ml_min.lcd




PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm Peak# Time Area Height Area % Height % 92.070 12.763 16531529 648808 95.327 24.558 1423871 31803 7.930 4.673 17955400 100.000 100.000 Total 680611





6/18/2012 18:24:33 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-192-ADH-15%IPA-1.5ml_min.lcd

Acquired by

: Admin : RAC-BAH-III-192-ADH-15%IPA-1.5ml_min Sample Name

Sample ID : <SAMPLE> Tray# Vail# : 1 Injection Volume : 1 uL


: RAC-BAH-III-192-ADH-15%IPA-1.5ml_min.lcd Data File Name

Method File Name : Cyclic Urea Method.lcm

Batch File Name


Report File Name

: Default.lcr : 6/15/2012 4:57:33 PM Data Acquired Data Processed : 6/15/2012 5:15:16 PM



<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-192-ADH-15%IPA-1.5ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.749	47039979	2993895	49.544	50.052
2	8.278	47905890	2987667	50.456	49.948
Total		94945869	5981562	100.000	100.000

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-117(III)-ADH-15%IPA-1.5mI_min.lcd : Admin : CHIRAL-BAH-III-117(III)-ADH-15%IPA-1.5ml_min

Acquired by Sample Name

Sample ID <SAMPLE> Tray# Vail# : 1

Injection Volume

Data File Name Method File Name : CHIRAL-BAH-III-117(III)-ADH-15%IPA-1.5ml_min.lcd

: Cyclic Urea Method.lcm

Batch File Name


Report File Name

: Default.lcr : 3/9/2012 4:39:55 PM Data Acquired Data Processed : 3/9/2012 5:03:22 PM

NO_2

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-117(III)-ADH-15%IPA-1.5ml_min.lcd





PDA Multi 1/198nm 4nm


PeakTable


PDA Ch1 198nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	7.459	28888734	2703157	87.952	91.063
2	7.874	3957164	265284	12.048	8.937
Total		32845898	2968441	100.000	100.000









C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-161-ADH-15%IPA-1.5ml_min.lcd

: Admin : RAC-BAH-III-181-ADH-15%IPA-1.5ml_min Acquired by Sample Name

Sample ID : <SAMPLE> Tray# : 1 : 1 Vail# : 1 uL

Injection Volume : RAC-BAH-III-161-ADH-15%IPA-1.5ml_min.lcd Data File Name

Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name : Default.lor


: 5/17/2012 2:13:45 PM : 5/17/2012 2:40:16 PM Data Acquired Data Processed

 NO_2

d-2m

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-161-ADH-15%IPA-1.5ml_min.lcd



1 PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	6.151	5884305	363565	50.295	56.586
2	9.335	5815254	278938	49.705	43.414
Total		11699559	642503	100.000	100.000

7/2/2012 19:03:31 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\BAH-iii-164-d2f.lcd

: Admin : BAH-iii-164-d2f Acquired by Sample Name Sample ID <SAMPLE> Tray#

Vail# Injection Volume

Data File Name BAH-iii-164-d2f.lcd Method File Name : Cyclic Urea Method.lcm

Batch File Name

Report File Name

Default.lor 7/2/2012 6:48:32 PM Data Acquired Data Processed : 7/2/2012 6:59:43 PM NO_2

d-2m


<Chromatogram>


C:\LabSolutions\Data\B. Hopkins\BAH-iii-164-d2f.lcd mAU PDA Multi 1 3000-2000 1000 min

PDA Multi 1/198nm 4nm

PeakTable

PDA Ch1 198nm 4nm							
Peak#	Ret. Time	Area	Height	Area %	Height %		
1	6.101	33242987	2983724	95.537	97.340		
2	9.185	1552846	81526	4.463	2.660		
Total		34795833	3065250	100.000	100.000		





C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-182-LUXAMYLOSE-10%IPA-1.0ml_min.lcd

Acquired by

: Admin : RAC-BAH-III-182-LUXAMYLOSE-10%IPA-1.0ml_min Sample Name

: <SAMPLE> Sample ID Tray#

Vail# Injection Volume

: RAC-BAH-III-182-LUXAMYLOSE-10%IPA-1.0ml_min.lcd Data File Name

Method File Name : Cyclic Urea Method.lcm


Batch File Name Report File Name Default.lor

6/11/2012 1:48:26 PM Data Acquired : 6/11/2012 2:36:15 PM Data Processed

6

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-182-LUXAMYLOSE-10%IPA-1.0ml_min.lcd



PDA Multi 1/210nm 4nm

PeakTable

PDA Ch1 210nm 4nm

Peak#	Ret. Time	Area	Height	Area %	Height %
1	21.161	12449205	382753	49.721	51.581
2	23.105	12588871	359291	50.279	48.419
Total		25038076	742044	100.000	100.000

6/18/2012 13:39:16 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-184-LUXAMYLOSE-10%IPA-1.0ml_min.lcd

Acquired by

: Admin : CHIRAL-BAH-III-184-LUXAMYLOSE-10%IPA-1.0ml_min Sample Name

: <SAMPLE> Sample ID

Tray# Vail# Injection Volume

Data File Name CHIRAL-BAH-III-184-LUXAMYLOSE-10%IPA-1.0ml_min.lcd

Method File Name Cyclic Urea Method.lcm

Batch File Name


Report File Name Default.lor

6/11/2012 3:27:03 PM Data Acquired Data Processed : 6/11/2012 3:53:15 PM

6

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\CHIRAL-BAH-III-184-LUXAMYLOSE-10%IPA-1.0ml_min.lcd



PDA Multi 1/210nm 4nm

PeakTable

PDA Ch1 210nm 4nm							
	Peak#	Ret. Time	Area	Height	Area %	Height %	
	1	21.304	3839790	132706	7.660	11.861	
	2	22.676	46287854	986107	92.340	88.139	
	Total		50127644	1118813	100.000	100.000	

7/1/2012 18:11:53 1 / 1

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-183-LUXAMYLOSE-10%IPA-1.0ml_min.lcd

Acquired by Sample Name

: RAC-BAH-III-183-LUXAMYLOSE-10%IPA-1.0ml_min


Sample ID : <SAMPLE> Tray# Vail# Injection Volume : 1 uL

Data File Name : RAC-BAH-III-183-LUXAMYLOSE-10%IPA-1.0ml_min.lod

Method File Name : Cyclic Urea Method.lcm

Batch File Name Report File Name : Default.lor


6/11/2012 2:39:30 PM Data Acquired Data Processed : 6/11/2012 3:17:28 PM



6 (from L-phenylalanine)

<Chromatogram>

C:\LabSolutions\Data\B. Hopkins\RAC-BAH-III-183-LUXAMYLOSE-10%IPA-1.0ml_min.lcd



PDA Multi 1/210nm 4nm

PeakTable

DD A	C11. 1	210	4
PDA	Cni	210nm	4nm

Direction and the second secon						
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	21.499	120677	4554	0.889	1.106	
2	23.023	13458652	407238	99.111	98.894	
Total		13579329	411792	100 000	100 000	